

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrXELODA[®]

capecitabine tablets

Tablets 150 mg and 500 mg

Manufacturer's Standard

Antineoplastic Agent

Hoffmann-La Roche Limited
7070 Mississauga Road
Mississauga, Ontario
L5N 5M8

Date of Initial Authorization:
September 10, 1998

Date of Revision:
April 19, 2021

www.rochecanada.com

Submission Control No: 247293

[®]Copyright 1998 – 2021 Hoffmann-La Roche Limited.
XELODA[®] is a registered trade-mark of F. Hoffmann-La Roche AG, used under license.

RECENT MAJOR LABEL CHANGES

4. DOSAGE AND ADMINISTRATION, 4.1 DOSING CONSIDERATIONS	07/2019
7. WARNINGS AND PRECAUTIONS	07/2019
7. WARNINGS AND PRECAUTIONS, 7.1 SPECIAL POPULATIONS	07/2019

RECENT MAJOR LABEL CHANGES	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1. INDICATIONS	4
1.1 Pediatrics.....	4
1.2 Geriatrics.....	5
2. CONTRAINDICATIONS	5
3. SERIOUS WARNINGS AND PRECAUTIONS BOX	5
4. DOSAGE AND ADMINISTRATION	6
4.1 Dosing Considerations	6
4.2 Recommended Dose and Dosage Adjustment	6
4.5 Missed Dose.....	11
5. OVERDOSAGE	11
6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	11
7. WARNINGS AND PRECAUTIONS	12
7.1 Special Populations.....	17
7.1.1 Pregnant Women.....	17
7.1.2 Breast-feeding	18
7.1.3 Pediatrics.....	18
7.1.4 Geriatrics.....	18
8. ADVERSE REACTIONS	18
8.1 Adverse Drug Reaction Overview	18
8.2 Clinical Trial Adverse Drug Reactions.....	19
8.3 Less Common Clinical Trial Adverse Drug Reactions.....	20
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data	27
8.5 Post-Market Adverse Reactions.....	31
9. DRUG INTERACTIONS	32
9.4 Drug-Drug Interactions	32
9.5 Drug-Food Interactions	33

10.	CLINICAL PHARMACOLOGY	33
10.1	Mechanism of Action	33
10.3	Pharmacokinetics	34
11.	STORAGE AND STABILITY	37
12.	SPECIAL HANDLING INSTRUCTIONS	37
PART II: SCIENTIFIC INFORMATION		38
13.	PHARMACEUTICAL INFORMATION	38
14.	CLINICAL TRIALS	38
14.1	Trial Design and Study Demographics	38
14.2	Study Results.....	39
15.	NON-CLINICAL TOXICOLOGY	47

PART I: HEALTH PROFESSIONAL INFORMATION

1. INDICATIONS

Caution: XELODA (capecitabine) is a potent drug and should be prescribed only by physicians experienced with cancer chemotherapeutic drugs.

XELODA (capecitabine) is indicated for:

Colorectal Cancer

Monotherapy

- XELODA (capecitabine) is indicated for the adjuvant treatment of patients with stage III (Dukes' stage C) colon cancer.
- XELODA is also indicated for the first-line treatment of patients with metastatic colorectal cancer.

Combination Therapy

XELODA in combination with oxaliplatin is indicated for the treatment of metastatic colorectal cancer following failure of irinotecan-containing combination chemotherapy.

In second-line metastatic disease, subgroup analyses for PFS and OS for age suggest that XELODA in combination with oxaliplatin may be less effective in patients over the age of 65. Clinical studies suggest an increase in the incidence of adverse events. See CLINICAL TRIALS and WARNINGS AND PRECAUTIONS.

Breast Cancer

Monotherapy

XELODA is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane, unless therapy with a taxane is clinically contraindicated.

Combination Therapy

XELODA in combination with docetaxel is indicated for the treatment of patients with advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

1.1 Pediatrics

Pediatrics (≥ 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of XELODA in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. (See CLINICAL TRIALS and Pharmacokinetics, Special Populations and Conditions).

1.2 Geriatrics

Geriatrics (≥ 65 years of age): Based on the population pharmacokinetic analysis which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65, age has no influence on the pharmacokinetics of 5'-DFUR and 5-FU. However, the elderly may be pharmacodynamically more sensitive to the toxic effects of 5-FU (see WARNINGS AND PRECAUTIONS, Geriatrics and DOSAGE AND ADMINISTRATION).

2. CONTRAINDICATIONS

Capecitabine is contraindicated in patients who are hypersensitive to this drug, or 5-fluorouracil, or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.

Capecitabine is contraindicated in patients who have:

- Severe renal impairment (calculated creatinine clearance below 30 mL/min, or 0.5 mL/s)
- Complete absence of dihydropyrimidine dehydrogenase (DPD) activity. Testing for DPD deficiency should be considered prior to treatment, based on the local availability and current guidelines (see WARNINGS and PRECAUTIONS/‘Dihydropyrimidine dehydrogenase (DPD) deficiency’ and ‘Monitoring and Laboratory Tests’).

Due to potentially fatal drug interaction, XELODA should not be administered concomitantly with sorivudine¹ or its chemically related analogues, such as brivudine.

If contraindications exist to any of the agents in a combination regimen, that agent should not be used.

3. SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

- Acute renal failure secondary to dehydration can be fatal. If Grade 2 (or higher) dehydration occurs, XELODA treatment should be immediately interrupted and the dehydration corrected (see Endocrine and Metabolism - Dehydration below).
- Similar to that of other fluorinated pyrimidines sudden death due to cardiotoxicity has been observed with XELODA (see Cardiovascular below).
- XELODA can induce severe skin reactions such as hand-and-foot syndrome, Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. If grade 2 (or higher) event occurs, administration of XELODA should be immediately interrupted (see Immune and Skin below).
- Severe toxicity (e.g. stomatitis, diarrhea, mucosal inflammation, neutropenia and neurotoxicity) associated with 5-FU has been attributed to a deficiency of DPD

¹ sorivudine and its chemically related analogues, such as brivudine are not authorized for sale in Canada.

activity, an enzyme involved in fluorouracil degradation. Fatalities have been reported. Testing for DPD deficiency should be considered prior to treatment, based on the local availability and current guidelines. (see Endocrine and Metabolism- DPD deficiency below).

- Altered coagulation parameters and/or bleeding have been reported in patients taking XELODA concomitantly with coumarin-derived anticoagulants such as warfarin. Patients taking coumarin-derivative anticoagulants concomitantly with XELODA should be monitored regularly for alterations in their coagulation parameters (PT or INR) and the anticoagulant dose adjusted accordingly (see Hematologic below).

4. DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- XELODA is intended for long-term administration unless clinically inappropriate.
- XELODA tablets should be swallowed whole with water within 30 minutes after a meal.
- XELODA tablets should not be crushed or cut (see ADVERSE REACTIONS, Postmarketing Reports of Adverse Events).
- If patients cannot swallow XELODA tablets whole and tablets must be crushed or cut, this should be done by a professional trained in the safe handling of cytotoxic drugs (see SPECIAL HANDLING INSTRUCTIONS).

4.2 Recommended Dose and Dosage Adjustment

- **Monotherapy:** The recommended dose of XELODA (capecitabine) is 1250 mg/m² administered twice daily (morning and evening; equivalent to 2500 mg/m² total daily dose) for 14 days followed by a seven day rest period.

For adjuvant treatment of stage III colon cancer, XELODA is intended to be given for a total of 8 cycles (or 24 weeks).

- **Colorectal Cancer, Combination Therapy with Oxaliplatin:** In combination with oxaliplatin the recommended dose of XELODA is 1000 mg/m² twice daily for 2 weeks followed by a 7-day rest period. The first dose of XELODA is given on the evening of day 1 and the last dose is given on the morning of day 15. Given as a 3-weekly schedule, oxaliplatin is administered as a 130 mg/m² intravenous infusion over 2 hours.

Premedication to maintain adequate anti-emesis according to the oxaliplatin Product Monograph should be started prior to oxaliplatin administration for patients receiving the XELODA plus oxaliplatin combination

- **Locally advanced and/or Metastatic Breast Cancer, Combination Therapy with Docetaxel:** In combination with docetaxel, the recommended starting dose of XELODA is 1250 mg/m² twice daily for 2 weeks followed by a 7-day rest period combined with

docetaxel 75 mg/m² administered as a 1-hour intravenous infusion every 3 weeks (see ACTIONS AND CLINICAL PHARMACOLOGY, CLINICAL TRIALS, Breast Carcinoma). Premedication according to the docetaxel labelling, should be started prior to docetaxel administration for patients receiving the XELODA plus docetaxel combination.

Dose calculation

XELODA dose is calculated according to body surface area. Tables 9 and 10 show examples of the standard and reduced dose calculations for a XELODA starting dose of either 1250 mg/m² or 1000 mg/m².

Table 9 Standard and reduced dose calculations according to body surface area for a starting XELODA dose of 1250 mg/m²

	Dose level 1250 mg/m ² (twice daily)				
	Full dose 1250 mg/m ²	Number of 150 mg tablets and/or 500 mg tablets per administration (each administration to be given morning and evening)		Reduced dose (75%) 950 mg/m ²	Reduced dose (50%) 625 mg/m ²
Body Surface Area (m ²)	Dose per administration (mg)	150 mg	500 mg	Dose per administration (mg)	Dose per administration (mg)
≤ 1.26	1500	-	3	1150	800
1.27 - 1.38	1650	1	3	1300	800
1.39 - 1.52	1800	2	3	1450	950
1.53 - 1.66	2000	-	4	1500	1000
1.67 - 1.78	2150	1	4	1650	1000
1.79 - 1.92	2300	2	4	1800	1150
1.93 - 2.06	2500	-	5	1950	1300
2.07 - 2.18	2650	1	5	2000	1300
≥ 2.19	2800	2	5	2150	1450

Table 10 Standard and reduced dose calculations according to body surface area for a starting XELODA dose of 1000 mg/m²

	Dose level 1000 mg/m ² (twice daily)				
	Full dose 1000 mg/m ²	Number of 150 mg tablets and/or 500 mg tablets per administration (each administration to be given morning and evening)		Reduced dose (75%) 750 mg/m ²	Reduced dose (50%) 500 mg/m ²
Body Surface Area (m ²)	Dose per administration (mg)	150 mg	500 mg	Dose per administration (mg)	Dose per administration (mg)
≤ 1.26	1150	1	2	800	600
1.27 - 1.38	1300	2	2	1000	600
1.39 - 1.52	1450	3	2	1100	750
1.53 - 1.66	1600	4	2	1200	800
1.67 - 1.78	1750	5	2	1300	800
1.79 - 1.92	1800	2	3	1400	900
1.93 - 2.06	2000	-	4	1500	1000
2.07 - 2.18	2150	1	4	1600	1050
≥ 2.19	2300	2	4	1750	1100

Dose Modification Guidelines

Patients should be carefully monitored for toxicity. Toxicity due to XELODA administration may be managed by symptomatic treatment, dose interruptions and adjustment of XELODA dose. Once the dose has been reduced it should not be increased at a later time.

For those toxicities considered by the treating physician to be unlikely to become serious or life-threatening, treatment can be continued at the same dose without reduction or interruption.

Dose modifications for the use of XELODA are shown in Table 11.

Table 11 Recommended Dose Modifications for XELODA

Toxicity NCIC Grade*	During a Course of Therapy	Dose Adjustment for Next Cycle (% of starting dose)
Grade 1	Maintain dose level	Maintain dose level
Grade 2		
-1 st appearance	Interrupt until resolved to grade 0-1	100%
-2 nd appearance	Interrupt until resolved to grade 0-1	75%
-3 rd appearance	Interrupt until resolved to grade 0-1	50%
-4 th appearance	Discontinue treatment permanently	
Grade 3		
-1 st appearance	Interrupt until resolved to grade 0-1	75%
-2 nd appearance	Interrupt until resolved to grade 0-1	50%
-3 rd appearance	Discontinue treatment permanently	
Grade 4		
-1 st appearance	Discontinue permanently <i>or</i> If physician deems it to be in the patient's best interest to continue, interrupt until resolved to grade 0-1	50%
-2 nd appearance	Discontinue permanently	

* According to the National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) Common Toxicity Criteria (Version 1 or the Common Terminology Criteria for Adverse Events (CTCAE) of the Cancer Therapy Evaluation Program, US National Cancer Institute, version 3.0. For Hand-and-Foot Syndrome and hyperbilirubinemia (see WARNINGS AND PRECAUTIONS)

Dosage modifications are not recommended for grade 1 events. Therapy with XELODA should be interrupted upon the occurrence of a grade 2 or 3 adverse experience. Once the adverse event has resolved or decreased in intensity to grade 1, then XELODA therapy may be restarted at full dose or as adjusted according to Table 11 for XELODA monotherapy. If a grade 4 event occurs, therapy should be discontinued or interrupted until resolved or decreased to grade 1, and therapy should be restarted at 50% of the original dose. Patients taking XELODA should be informed of the need to interrupt treatment immediately if moderate or severe toxicity occurs. Doses of XELODA omitted for toxicity are not replaced.

Haematology: Patients with baseline neutrophil counts of $<1.5 \times 10^9/L$ and/or thrombocyte counts of $<100 \times 10^9/L$ should not be treated with XELODA. If unscheduled laboratory assessments during a treatment cycle show grade 3 or 4 haematologic toxicity, treatment with XELODA should be interrupted.

Combination Therapy: Dose modifications for toxicity when XELODA is used in combination with other therapies should be made according to Table 11 above for XELODA and according to the appropriate Product Monograph for the other agent(s).

At the beginning of a treatment cycle, if a treatment delay is indicated for either XELODA or the other agent(s), then administration of all agents should be delayed until the requirements for restarting all drugs are met.

During a treatment cycle for those toxicities considered by the treating physician not to be related to XELODA, XELODA should be continued and the dose of the other agent adjusted according to the appropriate Product Monograph.

If the other agent(s) have to be discontinued permanently, XELODA treatment can be resumed when the requirements for restarting XELODA are met.

This advice is applicable to all indications and to all special populations.

Adjustment of Starting Dose in Special Populations

Hepatic Impairment: In patients with mild to moderate hepatic dysfunction due to liver metastases, no dose adjustment is necessary. Patients with severe hepatic dysfunction have not been studied (see WARNINGS AND PRECAUTIONS).

Renal Impairment: In patients with moderate renal impairment (calculated creatinine clearance 30-50 mL/min [Cockcroft and Gault]) at baseline, a dose reduction to 75% from a starting dose of 1250 mg/m² is recommended based upon pharmacokinetic and safety data (see ACTIONS AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Renal Insufficiency, and WARNINGS AND PRECAUTIONS). In patients with mild renal impairment (calculated creatinine clearance 51-80 mL/min) no adjustment in starting dose is recommended. In patients with severe renal impairment, XELODA should not be administered (see CONTRAINDICATIONS). Careful monitoring and prompt treatment interruption is recommended if the patient develops a grade 2, 3, or 4 adverse event, with subsequent dose adjustment as outlined in the tables above. If the calculated creatinine clearance decreases during treatment to a value below 30 mL/min, XELODA should be discontinued. The dose adjustment recommendation for patients with moderate renal impairment applies both to monotherapy and combination use. For dosage calculations, see Table 9.

Geriatrics: No adjustment of the starting dose is needed for XELODA. However for XELODA monotherapy in the metastatic setting, severe Grade 3 or 4 treatment-related adverse events were more frequent in patients over 80 years of age compared to younger patients. Careful monitoring of elderly patients is advisable.

When XELODA was used in combination with other agents, elderly patients (≥ 65 years) experienced more grade 3 and grade 4 adverse drug reactions (ADRs) and ADRs that led to discontinuation, than younger patients. Careful monitoring of elderly patients is advisable.

For treatment with XELODA in combination with docetaxel, an increased incidence of Grade 3 or 4 treatment-related adverse events and treatment-related serious adverse events was observed in patients 60 years of age or more.

4.5 Missed Dose

If you forget a dose of XELODA do not take the missed dose at all. Take your next dose at the usual time and check with your doctor. Do not take a double dose.

5. OVERDOSAGE

The manifestations of acute overdose include: nausea, vomiting, diarrhea, mucositis, GI irritation and bleeding, and bone marrow depression. Management of overdose should include customary therapeutic and supportive medical interventions aimed at correcting the presenting clinical manifestations and preventing their possible complications.

For management of a suspected drug overdose, contact your regional poison control centre.

6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength	Non-medicinal Ingredients
Oral	Tablets 150 mg and 500 mg	croscarmellose sodium, hydroxypropyl methylcellulose, iron oxides (yellow and red), lactose anhydrous, magnesium stearate, microcrystalline cellulose, talc, titanium dioxide.

Composition:

Each XELODA 150 mg and 500 mg tablet contains either 150 mg or 500 mg capecitabine, respectively. Non-medicinal ingredients (alphabetical order): croscarmellose sodium, hydroxypropyl methylcellulose, iron oxides (yellow and red), lactose anhydrous, magnesium stearate, microcrystalline cellulose, talc, titanium dioxide.

Packaging:

XELODA is available as a film-coated tablet in strengths of either 150 mg or 500 mg.

XELODA 150 mg tablets are light peach-coloured, biconvex, film-coated, oblong-shaped tablets with XELODA engraved on one side and 150 on the reverse. XELODA 150 mg tablets are available in HDPE bottles containing 60 tablets or in blister packs containing 60 tablets (10 tablets per blister card and 6 blister cards per carton).

XELODA 500 mg tablets are peach- coloured, biconvex, film-coated, oblong-shaped tablets with XELODA engraved on one side and 500 on the reverse. XELODA 500 mg tablets are available

in HDPE bottles containing 120 tablets or in blister packs containing 120 tablets (10 tablets per blister card and 12 blister cards per carton).

7. WARNINGS AND PRECAUTIONS

Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.

General

If toxicity on therapy occurs, XELODA should be interrupted until the event resolves, or the severity decreases when the following toxicities occur at a severity of grade 2 or greater: diarrhea, hand-foot syndrome, nausea, hyperbilirubinemia, vomiting or stomatitis (see DOSAGE AND ADMINISTRATION).

Patients and patients' caregivers should be informed of the expected adverse effects of XELODA, particularly of diarrhea, nausea, vomiting, and hand-and-foot syndrome and stomatitis. The frequent oral administration of XELODA allows patient specific dose adaptations during therapy (see DOSAGE AND ADMINISTRATION). Most adverse reactions are reversible and do not require discontinuation, although doses may need to be withheld or reduced (see DOSAGE AND ADMINISTRATION). Patients should be taught to recognize and report the common grade 2 toxicities associated with XELODA treatment (please refer to CONSUMER INFORMATION).

If XELODA is prescribed in combination with docetaxel, patients and patients' caregivers should be informed of the expected adverse effects of the combination of XELODA and docetaxel (see Table 11).

Diarrhea: Patients experiencing grade 2 diarrhea (an increase of 4 to 6 stools/day or nocturnal stools) or greater should be instructed to stop taking XELODA immediately. Standard antidiarrheal agents (e.g. loperamide) should be prescribed for symptom control (see DOSAGE AND ADMINISTRATION).

Nausea: Patients experiencing grade 2 nausea (food intake significantly decreased but able to eat intermittently) or greater should be instructed to stop taking XELODA immediately. Standard anti-nausea agents should be prescribed for symptom control (see DOSAGE AND ADMINISTRATION).

Vomiting: Patients experiencing grade 2 vomiting (2 to 5 episodes in a 24-hour period) or greater should be instructed to stop taking XELODA immediately. Standard anti-emetic agents should be prescribed for symptom control (see DOSAGE AND ADMINISTRATION).

Hand-and-Foot Syndrome: Patients experiencing grade 2 hand-and-foot syndrome (painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patients' activities of daily living) or greater should be instructed to stop taking XELODA immediately.

Stomatitis: Patients experiencing grade 2 stomatitis or greater (painful erythema, edema or ulcers, but are able to eat) should be instructed to stop taking XELODA immediately. Symptomatic treatment should be prescribed (see DOSAGE AND ADMINISTRATION).

Carcinogenesis and Mutagenesis

Although there was no evidence for oncogenic potential of capecitabine in a two-year carcinogenicity study in mice, capecitabine was clastogenic *in vitro* in human lymphocytes (similar to other nucleoside analogues such as 5-FU). There was also a positive trend in the *in vivo* mouse micronucleus assay (see TOXICOLOGY-Carcinogenicity, Mutagenicity, and Genotoxicity studies).

Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with XELODA (see Special Populations below) and be provided with appropriate counselling if not currently using contraceptives. Males are advised not to father a child during treatment.

Cardiovascular

The spectrum of cardiotoxicity observed with XELODA is similar to that of other fluorinated pyrimidines. This includes myocardial infarction, angina, dysrhythmias, cardiac arrest, sudden death, cardiomyopathy, cardiac failure, and electrocardiographic changes. These adverse events may be more common in patients with a prior history of coronary artery disease. A thorough QT interval prolongation assessment study of XELODA has not been conducted.

Driving and Operating Machinery

XELODA has moderate influence on the ability to drive and use machines. Patients should be advised to use caution when driving or using machines if they experience ADRs such as dizziness, fatigue, and or nausea during treatment with XELODA.

Endocrine and Metabolism

Dehydration

Dehydration should be prevented or corrected at the onset. Patients with anorexia, asthenia, nausea, vomiting or diarrhea may rapidly become dehydrated. If Grade 2 (or higher) dehydration occurs, XELODA treatment should be immediately interrupted and the dehydration corrected.² Treatment should not be restarted until the patient is rehydrated and any precipitating causes have been corrected or controlled. Dose modifications applied should be applied for the precipitating adverse event as necessary (see DOSAGE AND ADMINISTRATION section).

Dehydration may cause acute renal failure, especially in patients with pre-existing compromised renal function or when capecitabine is given concomitantly with known nephrotoxic agents. Fatal outcome of renal failure has been reported in these situations (see ADVERSE REACTIONS).

² NCIC grade 2 dehydration is defined as IV fluids indicated <24 hours, grade 3 dehydration is defined as IV fluids indicated ≥24 hours, grade 4 dehydration is defined as life-threatening consequences (e.g. hemodynamic collapse), and grade 5 dehydration as death.

Dihydropyrimidine dehydrogenase (DPD) deficiency

Patients with certain homozygous or certain compound heterozygous mutations in the DPYD gene locus that cause complete or near complete absence of DPD activity, are at the highest risk for severe, life-threatening, or fatal adverse reactions caused by fluorouracil. These patients should not be treated with XELODA. No dose has been proven safe for patients with complete absence of DPD activity (see CONTRAINDICATIONS).

Patients with certain heterozygous DPYD variants (eg. DPYD*2A variant) that may cause partial DPD deficiency have been shown to have increased risk of severe toxicity when treated with capecitabine. For patients with partial DPD deficiency where the benefits of XELODA are considered to outweigh the risks (taking into account the suitability of an alternative non-fluoropyrimidine chemotherapeutic regimen), these patients must be treated with extreme caution, initially with a substantial dose reduction and frequent subsequent monitoring and dose adjustment according to toxicity.

Testing for DPD deficiency should be considered prior to treatment, based on the local availability and current guidelines.

In patients with unrecognised DPD deficiency treated with capecitabine as well as patients who test negative for specific DPYD variations, life-threatening toxicities manifesting as acute overdose may occur. In the event of grade 2-4 acute toxicity, treatment must be discontinued immediately. Permanent discontinuation should be considered based on clinical assessment of the onset, duration and severity of the observed toxicities (see DOSAGE AND ADMINISTRATION).

Gastrointestinal

Diarrhea

XELODA very frequently induces diarrhea, which can sometimes be severe. Patients with severe diarrhea should be carefully monitored and, if they become dehydrated, should be given fluid and electrolyte replacement (see Monitoring and Laboratory tests). If grade 2 (or higher) diarrhea occurs, administration of XELODA should be immediately interrupted until diarrhea resolves or decreases in intensity to grade 1³. Standard antidiarrheal agents (e.g. loperamide) should be initiated, as medically appropriate, as early as possible. Dose reduction should be applied as necessary (see DOSAGE AND ADMINISTRATION section). Necrotizing enterocolitis (typhlitis) has been reported.

³ National Cancer Institute of Canada (NCIC) grade 1 diarrhea is defined as an increase of < 4 stools per day over baseline, mild increase in ostomy output compared to baseline, grade 2 diarrhea is defined as an increase of 4 to 6 stools/day or nocturnal stools, grade 3 diarrhea as an increase of 7 to 9 stools/day or incontinence and malabsorption, grade 4 diarrhea as an increase of 10 stools/day or grossly bloody diarrhea or the need for parenteral support, and grade 5 diarrhea as death.

Hematologic

In 251 patients with metastatic breast cancer who received XELODA in combination with docetaxel, 68% had grade 3 or 4 neutropenia, 2.8% had grade 3 or 4 thrombocytopenia and 9.6% had grade 3 or 4 anemia.

In 875 patients with either metastatic breast or colorectal cancer who received XELODA monotherapy, 3.2%, 1.7%, and 2.4% of patients had grade 3/4 neutropenia, thrombocytopenia and decreases in hemoglobin, respectively.

Patients with baseline neutrophil counts of $<1.5 \times 10^9/L$ and/or thrombocyte counts of $<100 \times 10^9/L$ should not be treated with XELODA (see DOSAGE AND ADMINISTRATION - Haematology).

Altered coagulation parameters and/or bleeding have been reported in patients taking XELODA concomitantly with coumarin-derived anticoagulants such as warfarin. These events occurred within several days and up to several months after initiating XELODA therapy, and, in a few cases, within one month after stopping XELODA. These events occurred in patients with and without liver metastases (see Monitoring and Laboratory Tests and DRUG INTERACTIONS: *Coumarin Anticoagulants*).

Hepatic/Biliary/Pancreatic

Hepatic Insufficiency

Patients with hepatic impairment should be carefully monitored when XELODA is administered (see Monitoring and Laboratory Tests). However, the effect of hepatic impairment not due to liver metastases or of severe hepatic impairment on the disposition of XELODA is not known.

Hyperbilirubinemia

In 251 patients with metastatic breast cancer who received a combination of XELODA and docetaxel, grade 3 and 4 hyperbilirubinemia occurred in 6.8% (n=17) and 2% (n=5), respectively.

In 875 patients with either metastatic breast or colorectal cancer treated with XELODA monotherapy, grade 3 hyperbilirubinemia occurred in 133 (15.2%) and grade 4 hyperbilirubinemia occurred in 34 (3.9%) patients with either metastatic breast or colorectal cancer. If drug related grade 2, 3 or 4[†] elevations in bilirubin occur, administration of XELODA should be immediately interrupted until the hyperbilirubinemia resolves or decreases in intensity to grade 1. Following grade 3 or 4 hyperbilirubinemia, subsequent doses of XELODA should be decreased (see DOSAGE AND ADMINISTRATION).

Immune

XELODA can induce severe skin reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) (see ADVERSE REACTIONS). XELODA should be permanently

discontinued in patients who experience a severe skin reaction possibly attributable to XELODA treatment.

Rarely, unexpected and potentially fatal severe toxicities including neutropenia leading to local and fatal systemic infections following exposure to XELODA have been observed.

Monitoring and Laboratory Tests

- Testing for DPD deficiency should be considered prior to treatment, based on the local availability and current guidelines. (See WARNINGS AND PRECAUTIONS/DPD deficiency)
- Patients taking coumarin-derivative anticoagulants concomitantly with XELODA should be monitored regularly for alterations in their coagulation parameters (PT or INR) and the anticoagulant dose adjusted accordingly (see DRUG INTERACTIONS: Coumarin Anticoagulants).
- Careful monitoring of patients ≥ 60 years of age is advisable (see WARNINGS AND PRECAUTIONS: Geriatrics).
- Patients with severe diarrhea should be monitored for symptoms of dehydration (see WARNINGS AND PRECAUTIONS: Gastrointestinal and Endocrine and Metabolism)
- Patients with hepatic impairment or renal insufficiency should be carefully monitored when XELODA is administered (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION: Hepatic Impairment)
- Patients should be carefully monitored for toxicity (see DOSAGE AND ADMINISTRATION- Dose Modification Guidelines).
- Pregnancy testing is recommended for females of reproductive potential prior initiating XELODA. (See WARNINGS AND PRECAUTIONS/Special Populations)
- Patients taking phenytoin concomitantly with XELODA should be regularly monitored for increased phenytoin plasma concentrations. (See Drug Interactions)

Neurologic

Very rare adverse drug reaction leukoencephalopathy has been identified during post-marketing exposure.

Renal

Renal Insufficiency

Physicians should exercise caution when XELODA is administered to patients with impaired renal function. As seen with 5-FU, the incidence of treatment-related grade 3 or 4 adverse events was higher in patients with moderate renal impairment (calculated creatinine clearance 30-50 mL/min).

Reproductive Health: Female and Male Potential

- **Fertility:** Based on evidence from animal studies, Xeloda may impair fertility in females and males of reproductive potential (see TOXICOLOGY).
- **Females:** Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with XELODA and be provided with appropriate counselling if not currently using contraceptives. An effective method of contraception should be used during treatment and for 6 months after the last dose of XELODA. If the patient becomes pregnant while receiving XELODA, the potential hazard to the fetus must be explained. Pregnancy testing is recommended for females of reproductive potential prior initiating XELODA. (See Monitoring and Laboratory tests)
- **Males:** Based on genetic toxicity findings, male patients with female partners of reproductive potential should use effective contraception during treatment and for 3 months following the last dose of XELODA.

Skin

Hand-and-Foot Syndrome

Hand-and-foot syndrome (palmar-plantar erythrodysesthesia or chemotherapy induced acral erythema) can occur in patients receiving XELODA either as monotherapy or in combination therapy. Persistent or severe hand-foot syndrome (grade 2 and above) can eventually lead to loss of fingerprints, which could impact patient identification. For patients receiving XELODA monotherapy in the metastatic setting, median time to onset was 79 days (range from 11 to 360 days) with a severity range of grades 1 to 3*. If grade 2 or 3 hand-and-foot syndrome occurs, administration of XELODA should be interrupted until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-and-foot syndrome, subsequent doses of XELODA should be decreased (see DOSAGE AND ADMINISTRATION). For XELODA in combination with docetaxel, hand-and-foot syndrome was more common in patients in the combination therapy arm than in the monotherapy arm (63% vs. 8%).

7.1 Special Populations

7.1.1 Pregnant Women

There are no adequate and well-controlled studies in pregnant women using XELODA. If the drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus (see Carcinogenesis and Mutagenesis above). XELODA was found to be teratogenic and embryolethal in mice and embryolethal in monkeys (see TOXICOLOGY).

* Grade 1 hand-and-foot syndrome is defined by numbness, dysesthesia/paresthesia, tingling, or erythema of the hands and/or feet and/or discomfort which does not disrupt normal activities. Grade 2 hand-and-foot syndrome is defined as painful erythema and swelling of the hands and/or feet that results in discomfort affecting the patient's activities of daily living and grade 3 hand-and-foot syndrome is defined as moist desquamation, ulceration, blistering or severe pain of the hands and/or feet that results in severe discomfort that causes the patient to be unable to work or perform activities of daily living.

7.1.2 Breast-feeding

No studies have been conducted to assess the impact of XELODA on milk production or its presence in human breast milk. In a study of single oral administration of capecitabine in lactating mice, it was found that a significant amount of the capecitabine metabolites is transferred to the milk. Because of the potential for serious adverse reactions in nursing infants, it is recommended that nursing be discontinued when receiving XELODA therapy and for 2 weeks after the final dose.

7.1.3 Pediatrics

Pediatrics: (<18 years of age): The safety and effectiveness of XELODA in persons <18 years of age has not been established.

7.1.4 Geriatrics

XELODA in Combination with Docetaxel: An analysis of safety data in patients equal to or greater than 60 years of age showed an increase in the incidence of treatment-related Grade 3 and 4 adverse events, treatment-related serious adverse events and early withdrawals from treatment due to adverse events compared to patients less than 60 years of age. The incidence of grade 3 or 4 stomatitis was greater in the 60 to 70 year old patient group (30%) than the general population (13%) (see DOSAGE AND ADMINISTRATION).

XELODA in Combination with Oxaliplatin: In the second-line setting, subgroup analyses for PFS (EP population) and OS (ITT population) for age suggest that XELOX may be less effective than FOLFOX-4 in patients ≥ 65 years of age (HR 1.32, 95% CI, 0.98-1.78 and HR 1.34, 95% CI, 1.00-1.80, respectively). Physicians are advised to assess risks and benefits in these patients.

In the second-line setting, an analysis of safety data in patients equal to or greater than 65 years of age showed an increase in the incidence of treatment related serious adverse events, treatment related Grade 3 and 4 adverse events, gastrointestinal grade 3/4 events (particularly diarrhea), and patients who discontinued trial treatment. In addition, deaths up to 60 days after treatment start and deaths up to 28 days after last dose were slightly higher in older patients (see Monitoring and Laboratory Tests).

XELODA Monotherapy: Patients ≥ 80 years old may experience a greater incidence of gastrointestinal grade 3/4 events (see DOSAGE AND ADMINISTRATION).

8. ADVERSE REACTIONS

8.1 Adverse Drug Reaction Overview

Adverse drug reactions (ADRs) considered by the investigator to be possibly, probably, or remotely related to the administration of XELODA have been obtained from clinical studies conducted with XELODA monotherapy (in adjuvant therapy of colon cancer, in metastatic

colorectal cancer and metastatic breast cancer), and clinical studies conducted with XELODA in combination with docetaxel (metastatic breast cancer) or in combination with oxaliplatin (metastatic colorectal cancer).

8.2 Clinical Trial Adverse Drug Reactions

Colorectal Cancer, Monotherapy

Adjuvant Colon Cancer

Safety data of XELODA monotherapy were reported from one phase III trial in adjuvant colon cancer (995 patients treated with XELODA and 974 treated with i.v. 5FU/LV). The most frequently reported treatment related adverse events ($\geq 10\%$) for XELODA in this trial were gastrointestinal disorders, especially diarrhea, stomatitis, nausea, vomiting, hand-foot syndrome, fatigue and lethargy. The most frequent treatment-related undesirable effects ($\geq 5\%$) reported in this trial are presented in the following table (Table 1).

Table 1 Summary of ADRs Reported in $\geq 5\%$ of Patients with Colon Cancer Treated with XELODA Monotherapy or i.v. 5-FU/LV in the Adjuvant Setting

Adverse Event	XELODA 1250 mg/m ² /bid (n=995)		i.v. 5-FU/LV* (n= 974)	
	Total %	Grade 3/4 %	Total %	Grade 3/4 %
Gastrointestinal				
Diarrhea	46	11	64	13
Stomatitis	22	2	60	14
Nausea	33	2	47	2
Vomiting	14	2	20	1
Abdominal pain	10	2	13	1
Constipation	6	-	7	<1
Abdominal pain upper	6	<1	5	<1
Dyspepsia	5	<1	4	-
Skin and Subcutaneous				
Hand-foot Syndrome**	60	17	9	<1
Alopecia	6	-	22	<1
Rash	6	-	8	-
Erythema	6	1	5	<1
General Disorders				
Fatigue	15	<1	15	1
Lethargy	10	<1	9	<1
Asthenia	9	<1	9	1
Pyrexia	4	<1	6	<1
Nervous System Disorders				
Dysgeusia	6	-	9	-
Dizziness	5	<1	4	-
Metabolism and Nutrition Disorders				
Anorexia	9	<1	10	<1

Adverse Event	XELODA 1250 mg/m ² /bid (n=995)		i.v. 5-FU/LV* (n= 974)	
	Total %	Grade 3/4 %	Total %	Grade 3/4 %
Eye				
Conjunctivitis	5	<1	5	<1
Blood and Lymphatic System				
Neutropenia	2	<1	8	5

*Mayo Clinic regimen

** Based on the post-marketing experience, persistent or severe palmar-plantar erythrodysesthesia syndrome (grade 2 and above) can eventually lead to loss of fingerprints (see WARNINGS AND PRECAUTIONS).

8.3 Less Common Clinical Trial Adverse Drug Reactions

Rare or uncommon clinically relevant adverse reactions reported in <5% of metastatic colorectal cancer patients treated with XELODA in combination with oxaliplatin (second-line), that were considered at least remotely related to treatment are shown below. Occurrences of each grade 3 and 4 adverse event are provided in parentheses.

Gastrointestinal: intestinal obstruction (2%)

Nervous: peripheral motor neuropathy (<1%), encephalopathy (<1%)

Blood & Lymphatic: febrile neutropenia (<1%), pancytopenia (<1%)

Respiratory: pulmonary embolism (<1%), laryngospasm (<1%), bronchospasm (<1%)

Vascular: thrombosis (<1%), deep vein thrombosis (<1%), embolism (<1%)

Psychiatric: anxiety (<1%)

Renal & urinary: renal failure acute (<1%)

Hepatobiliary: hepatic failure (<1%)

Cardiac: myocardial infarction (<1%)

Breast Cancer, XELODA Monotherapy

The following data (Table 5) are for the study in stage IV breast cancer patients who received a dose of 2500 mg/m² administered daily for 2 weeks followed by a 1-week rest period. The mean duration of treatment was 121 days. A total of 71 patients (13%) discontinued treatment because of adverse events/intercurrent illness.

Table 5 XELODA Monotherapy: Percent Incidence of Adverse Reactions in $\geq 5\%$ of Patients Participating in the Phase II Trial in Stage IV Breast Cancer

Body System/ Adverse Event	NCIC Grade		
	1 to 4	3	4
GI			
Diarrhea	57	12	3
Nausea	53	4	-
Vomiting	37	4	-
Stomatitis	24	7	-
Abdominal pain	20	4	-
Constipation	15	1	-
Dyspepsia	8	-	-
Skin and Subcutaneous			
Hand-and-Foot Syndrome*	57	11	-
Dermatitis	37	1	-
Nail disorder	7	-	-
General			
Fatigue	41	8	-
Pyrexia	12	1	-
Pain in limb	6	1	-
Neurological			
Paraesthesia	21	1	-
Headache	9	1	-
Dizziness	8	-	-
Insomnia	8	-	-
Metabolism			
Anorexia	23	3	-
Dehydration	7	4	1
Eye			
Eye irritation	15	-	-
Musculoskeletal			
Myalgia	9	-	-
Cardiac			
Edema	9	1	-
Blood			
Neutropenia	26	2	2
Thrombocytopenia	24	3	1
Anemia	72	3	1
Lymphopenia	94	44	15
Hepatobiliary			
Hyperbilirubinemia	22	9	2

* Based on the post-marketing experience, persistent or severe palmar-plantar erythrodysesthesia syndrome (grade 2 and above) can eventually lead to loss of fingerprints (see WARNINGS AND PRECAUTIONS).

Locally advanced and/or Metastatic Breast Cancer, Combination with Docetaxel

The following data (Table 6) are for the combination study with XELODA and docetaxel in patients with locally advanced and/or metastatic breast cancer. In the XELODA -Docetaxel combination arm, the treatment was XELODA administered orally 1250 mg/m² twice daily as intermittent therapy (2 weeks of treatment followed by one week without treatment) for at least 6 weeks and docetaxel administered as a 1 hour intravenous infusion at a dose of 75 mg/m² on the

first day of each 3 week cycle for at least 6 weeks. In the monotherapy arm, docetaxel was administered as a 1 hour intravenous infusion at a dose of 100 mg/m² on the first day of each 3 week cycle for at least 6 weeks. The mean duration of treatment was 129 days in the combination arm and 98 days in the monotherapy arm. A total of 66 patients (26%) in the combination arm and 49 (19%) in the monotherapy arm withdrew from the study because of adverse events. The percentage of patients requiring dose reductions due to adverse events were 65% in the combination arm and 36% in the monotherapy arm. The hospitalization rate for treatment-related adverse events was 28.7% in the combination arm and 26.3% in the monotherapy arm.

Table 6 Per Cent Incidence of Adverse Reactions in ≥5% of Patients Participating in the Combination Study of XELODA and Docetaxel in Metastatic Breast Cancer

Adverse Event	XELODA 1250 mg/m ² /bid (Intermittent Regimen)with Docetaxel 75 mg/m ² /3 weeks (n=251)			Docetaxel 100 mg/m ² /3 weeks (n=255)		
	NCIC Grade					
Body System/Adverse Event	Total %	Grade 3 %	Grade 4 %	Total %	Grade 3 %	Grade 4 %
GI						
Stomatitis	67	17.1	0.4	43	4.7	-
Diarrhea	64	13.5	0.4	45	5.4	0.4
Nausea	43	6.4	-	35	2.0	-
Vomiting	33	3.6	0.8	22	0.8	-
Constipation	14	1.2	-	12	-	-
Abdominal pain	14	2.0	-	9	0.8	-
Dyspepsia	12	-	-	5	0.4	-
Abdominal Pain Upper	9	-	-	6	-	-
Dry mouth	5	0.4	-	4	-	-
Skin and Subcutaneous						
Hand-and-Foot Syndrome	63	24.3	-	8	1.2	-
Alopecia	41	6.0	-	42	6.7	-
Nail disorder	14	2.0	-	15	-	-
Dermatitis	8	-	-	9	0.8	-
Rash erythematous	8	0.4	-	4	-	-
Nail discolouration	6	-	-	4	0.4	-
Onycholysis	5	1.2	-	5	0.8	-
Pruritis	2	-	-	5	-	-
General						
Pyrexia	21	0.8	-	29	0.4	-
Asthenia	23	3.2	0.4	22	5.5	-
Fatigue	21	4.4	-	25	5.1	-
Weakness	13	1.2	-	9	2.0	-
Pain in limb	9	0.4	-	8	0.4	-
Lethargy	6	-	-	5	1.2	-
Pain	6	-	-	2	-	-

Adverse Event	XELODA 1250 mg/m ² /bid (Intermittent Regimen)with Docetaxel 75 mg/m ² /3 weeks (n=251)			Docetaxel 100 mg/m ² /3 weeks (n=255)		
	NCIC Grade					
Body System/Adverse Event	Total %	Grade 3 %	Grade 4 %	Total %	Grade 3 %	Grade 4 %
Neurological						
Dysgeusia	15	0.4	-	14	0.4	-
Headache	7	0.4	-	8	-	-
Paraesthesia	11	0.4	-	15	0.8	-
Dizziness*	9	-	-	6	0.4	-
Insomnia	4	-	-	5	0.4	-
Peripheral Neuropathy	5	-	-	10	0.8	-
Hypoaesthesia	4	-	-	7	0.4	-
Metabolism						
Anorexia	12	0.8	-	10	0.8	-
Appetite Decreased	10	-	-	4	-	-
Dehydration	8	2.0	-	5	0.4	0.4
Eye						
Lacrimation increased	12	-	-	5	-	-
Musculoskeletal						
Arthralgia	11	1.2	-	18	2.4	-
Myalgia	14	1.6	-	24	2.0	-
Back pain	7	0.8	-	6	0.8	-
Cardiac						
Edema lower limb	14	0.8	-	12	1.2	-
Edema NOS	4	-	-	5	-	0.8
Edema peripheral	4	-	-	5	0.4	-
Hematologic						
Neutropenia	17	4.8	10.8	16	2.7	11.8
Neutropenic fever	16	2.8	13.1	21	4.7	16.1
Anaemia	13	2.8	0.8	11	3.9	-
Respiratory						
Dyspnea	7	0.8	-	9	0.4	-
Cough	6	0.4	-	9	-	-
Sore throat	11	1.6	-	7	0.4	-
Epistaxis	5	0.4	-	5	-	-
Infections and Infestations						
Oral Candidiasis	6	0.4	-	7	0.4	-

- Not observed or applicable.

* Excluding vertigo

Listed below by body system are the adverse events in <5% of patients in the overall clinical trial safety database of 251 patients reported as related to the administration of XELODA in combination with docetaxel and that were clinically at least remotely relevant. In parentheses is the incidence of grade 3 and 4 occurrences of each adverse event.

Gastrointestinal: hemorrhoids (0.39), ileus (0.39), necrotizing enterocolitis (0.39), esophageal ulcer (0.39), hemorrhagic diarrhea (0.80)

General: rigors (0.39), injection site infection (0.39), neuralgia (0.39)

Neurological: ataxia (0.39), syncope (1.20), taste loss (0.80), polyneuropathy (0.39), migraine (0.39)

Cardiac: supraventricular tachycardia (0.39)

Infection: neutropenic sepsis (2.39), lower respiratory tract infection NOS (0.39), pharyngitis (0.39), otitis media (0.39), sepsis (0.39), bronchopneumonia (0.39)

Blood and Lymphatic: agranulocytosis (0.39), prothrombin decreased (0.39)

Vascular: hypotension (1.20), venous phlebitis & thrombophlebitis (0.39), blood pressure increase (0.39), postural hypotension (0.80)

Renal: renal failure (0.39)

Hepatobiliary: jaundice (0.39), abnormal liver function tests (0.39), hepatic failure (0.39), hepatic coma (0.39), hepatotoxicity (0.39)

Immune System: hypersensitivity (1.20)

XELODA Monotherapy Metastatic Breast and Colorectal Cancer

Listed below by body system are the clinical adverse events in <5% of 875 patients (phase III colorectal studies - 596 patients, phase II colorectal study - 34 patients, phase II breast cancer monotherapy studies - 245 patients) reported as related to the administration of XELODA and that were clinically at least remotely relevant.

In parentheses is the incidence of grade 3 or 4 occurrences of each adverse event.

Gastrointestinal: abdominal distension, esophagitis (0.2), intestinal obstruction (0.3), dysphagia, proctalgia, hemorrhoids, fecal abnormality, tongue disorder, ascites (0.1), gastric ulcer (0.1), gastrointestinal hemorrhage (0.2), ileus (0.3), incisional hernia, rectal disorder, swallowing painful, toxic dilation of intestine, melena, gastroenteritis (0.1), flatulence, gastritis, duodenitis, colitis

Skin and Subcutaneous: nail disorder (0.1), sweating increased (0.1), face edema, photosensitivity reaction (0.1), urticaria, skin ulcer, genital pruritus, skin lesion, ecchymoses, hyperkeratosis, intertrigo, leg ulcer (excluding varicose), localized skin reaction, red face, rosacea, scab, foot ulcer (0.1), dry skin (<0.01), localized exfoliation, skin hyperpigmentation, skin fissures (< 0.02)

General: shivering, chest pain (0.2), influenza-like illness, hot flushes, palmar erythema, hiccups, pain (0.1), hoarseness, fluid retention, irritability, difficulty in walking, thirst, chest mass, collapse, fibrosis (0.1), hemorrhage, neck edema, sedation, sudden death unexplained (0.1), swelling, ulcer (0.1)

Neurological: insomnia, ataxia (0.5), sedation, syncope (0.1), tremor, dysphasia, encephalopathy (0.1), coordination abnormal, dysarthria, facial palsy, loss of consciousness (0.2), mental impairment, myoclonic jerks, peroneal nerve palsy (0.1), headache (0.5)

Metabolism: weight increase, malnutrition (0.2), appetite increased, food intolerance (0.1), hypertriglyceridemia (0.1), hypokalemia, diabetes control impaired (0.1), hypomagnesemia

Eye: vision abnormal, cataract

Respiratory: cough (0.1), epistaxis (0.1), sore throat, chest tightness, rhinitis, increased sputum production, bronchospasm (0.2), hemoptysis, nasal ulcer, pneumothorax, crackles, orthopnea, pharyngeal disorder, pleural disorder, respiratory distress (0.1), sneezing

Cardiac: tachycardia (0.1), bradycardia, arrhythmia, chest pain (cardiac) (0.2), atrial fibrillation, cardiac failure, cardiomyopathy, extrasystoles, myocardial/infarction (0.1), myocarditis (0.1), pericardial effusion

Infection: herpes simplex, upper respiratory tract infection (0.1), urinary tract infection (0.2), localized infection, sepsis (0.3), bronchitis (0.1), lower respiratory tract infection, cellulitis, fungal infection (0.3), pneumonia (0.1), bronchopneumonia (0.1), herpes zoster, infection (0.1), influenza, keratoconjunctivitis, laryngitis (0.1), superinfection, immune system compromise, and/or disruption of mucous membranes, such as local and fatal systemic infections (including bacterial, viral, fungal etiologies) and sepsis

Musculoskeletal: myalgia, back pain, arthralgia (0.1), bone pain (0.1), neck pain, arthritis (0.1), calcaneal spur, muscle weakness

Blood and Lymphatic: leucopenia (0.2), coagulation disorder (0.1), bone marrow depression (0.1), idiopathic thrombocytopenia purpura (1.0), pancytopenia (0.1)

Vascular: hypotension (0.2), hypertension (0.1), flushing, lymphoedema (0.1), hematoma, pulmonary embolism (0.2), cerebrovascular accident (0.1), transient ischemic attack, varicose veins, venous thrombosis (0.8)

Psychiatric: depression, confusion (0.1), amnesia, libido decreased, loss of confidence, mood alteration, personality change, psychogenic disorder

Renal: dysuria, urinary incontinence, hematuria, hydronephrosis (0.1), nocturia (0.1), urinary tract disorder, urine discolouration, polyuria, renal impairment (0.1), urinary retention

Reproductive System: intermenstrual bleeding, balanoposthitis, vaginal pain, nipple disorder, premenstrual tension syndrome

Ear: vertigo, earache, deafness, sensation of block in ear

Hepatobiliary: jaundice (0.3), hepatomegaly, hepatic pain, fatty liver, bile duct stone (0.1), hepatic fibrosis (0.1), hepatitis (0.1), hepatic cholestatic (0.1)

Injury and Poisoning: radiation recall syndrome (0.1), bruising, overdose, scratch

Surgical: paronychia drainage, postoperative complications, wound drainage increased

Immune System: food allergy, hypersensitivity (0.1)

Endocrine: cushingoid, hypothyroidism, hirsutism

Neoplasms: lipoma, solar keratosis (0.1)

The following table (Table 7) displays laboratory abnormalities observed in 949 patients, regardless of relationship to treatment with XELODA in metastatic breast and colorectal cancer.

Table 7 Laboratory Abnormalities^a: XELODA Monotherapy in Metastatic Breast and Colorectal Cancer.

Parameter ^a	XELODA 1250 mg/m ² twice daily intermittent N=949			
	Patients with Grade 3 / 4 abnormality (%)	Patients with worsening from baseline of any grade (%)	Patients with worsening from baseline by 1 or 2 grades (%)	Patients with worsening from baseline by 3 or 4 grades (%)
Decreased hemoglobin	3.1	41.4	40.7	0.7
Decreased neutrophils	3.6	18.7	15.6	3.1
Decreased granulocytes	0.2	1.9	1.7	0.2
Decreased lymphocytes	44.4	58.2	53.1	5.1
Decreased platelets	2.0	20.4	18.8	1.6
Increased bilirubin	17.7	36.9	21.6	15.3
Increased ALAT (SGPT)	0.5	16.7	16.3	0.4
Increased ASAT (SGOT)	1.1	25.1	24.8	0.3
Increased serum creatinine	0.5	9.8	9.4	0.4
Increased alkaline phosphatase	3.5	27.2	27.2	0.0
Hyperglycemia	4.4	40.1	39.2	0.9

^a Laboratory abnormalities were graded according to the categories of the NCIC CTC Grading System.

Adverse Events Occurring in Special Patient Populations in Clinical Trials with XELODA Monotherapy in the Metastatic Setting

Geriatrics: Among the 21 patients (80 years of age and greater) with either metastatic breast or colorectal cancer who received XELODA monotherapy (N=875), 6 (28.6%), 3 (14.3%), and 2 (9.5%) patients experienced reversible grade 3/4 diarrhea, nausea and vomiting, respectively. Among the 496 patients aged 60 to 79 years old, the incidence of gastrointestinal toxicity was similar to that in the overall population. Patients 70 to 79 years old (22%) had a higher incidence of hand-and-foot syndrome.

Hyperbilirubinemia: In 875 patients with either metastatic breast or colorectal cancer who received at least one dose of capecitabine 2500 mg/m² daily for 2 weeks followed by a 1-week rest period, grade 3 hyperbilirubinemia occurred in 133 (15.2%) and grade 4 hyperbilirubinemia occurred in 34 (3.9%) patients. Grade 3/4 hyperbilirubinemia occurred in 22.8% of the 566 patients with hepatic metastases and in 12.3% of the 309 patients without hepatic metastases at baseline. Of the 167 patients with grade 3 or 4 hyperbilirubinemia, 31 (18.6%) also had post-baseline elevations (grades 1 to 4, without elevations at baseline) in alkaline phosphatase and 46 (27.5%) had post-baseline elevations in transaminases at any time (not necessarily concurrent). The majority of these patients, 20 (64.5%) and 33 (71.7%), had liver metastases at baseline. In addition, 96 (57.5%) and 59 (35.3%) of the 167 patients had elevations (grades 1 to 4) at both pre- and post-baseline in alkaline phosphatase or transaminases, respectively. Only 13 (7.8%) and 5 (3.0%) had grade 3 or 4 elevations in alkaline phosphatase or transaminases.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

The following table (Table 2) displays laboratory abnormalities observed in 995 patients, regardless of relationship to treatment, with XELODA in the adjuvant treatment of colon cancer.

Table 2 Laboratory Abnormalities^a: XELODA Monotherapy in Adjuvant Colon Cancer

Parameter	XELODA 1250 mg/m ² twice daily intermittent N=995			
	Patients with Grade 3/4 abnormality (%)	Patients with worsening from baseline of any grade (%)	Patients with worsening from baseline by 1 or 2 grades (%)	Patients with worsening from baseline by 3 or 4 grades (%)
Increased ALAT (SGPT)	1.6	27.2	25.9	1.3
Increased ASAT (SGOT)	0.7	28.7	28	0.7
Increased alkaline phosphatase	0.1	26.0	25.9	0.1
Increased calcium	1.1	5.2	4.8	0.4
Decreased calcium	2.3	13.2	12.4	0.8
Decreased granulocytes	0.3	2.0	1.7	0.3
Decreased hemoglobin	1.1	27.8	27.7	0.1
Decreased lymphocytes	13	51.3	49.2	2.1
Decreased neutrophils	2.2	30.3	28.4	1.9
Decreased neutrophils/granulocytes	2.4	31.0	28.9	2.1
Decreased platelets	1.0	17.3	16.8	0.5
Decreased Potassium	0.3	19.9	19.7	0.2
Increased serum creatinine	0.1	13.8	13.8	0
Decreased Sodium	0.4	17.5	17.1	0.4
Increased bilirubin	20	50.3	31.7	18.6

*The incidence of grade 3/4 white blood cell abnormalities was 1.3% in the XELODA arm and 4.9% in the I.V. 5-FU/LV arm.

^a Laboratory abnormalities were graded according to the categories of the NCIC CTC Grading System.

Metastatic Colorectal Cancer

Presented in the following table (Table 3) are the most frequent adverse reactions ($\geq 5\%$) with intensity reported as related (remotely, possibly or probably) to the administration of XELODA (capecitabine) or 5-FU/leucovorin (LV). Rates are rounded to the nearest whole number. The data shown are from pooled phase III metastatic colorectal cancer trials, in which a total of 605 patients with metastatic colorectal cancer were treated with 2500 mg/m²/day of XELODA administered for 2 weeks followed by a 1-week rest period and 604 patients were administered 5-FU and leucovorin in the Mayo regimen (20 mg/m² leucovorin I.V. followed by 425 mg/m²

I.V. bolus 5-FU, on days 1 to 5, every 28 days. The adverse event profile of 5-FU/LV in this study was consistent with the published literature. In the pooled colorectal database the median duration of treatment was 139 days for capecitabine treated patients and 140 days for 5-FU/LV treated patients. A total of 78 (13%) and 63 (11%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse event/intercurrent illness.

Table 3 Pooled Phase III Metastatic Colorectal Trials of XELODA Monotherapy vs. 5-FU/LV: Percent Incidence of Adverse Reactions in $\geq 5\%$ of Patients

Adverse Event	XELODA (n=596)			5-FU/LV (n=593)		
Body System/ Adverse Event	NCIC Grade					
	1 to 4	3	4	1 to 4	3	4
GI						
Diarrhea All	49	12	2	59	10	2
Nausea	38	3	-	47	2	-
Vomiting	23	3	-	27	3	-
Stomatitis All	25	2	-	62	14	1
Abdominal Pain	17	4	-	16	2	-
Gastrointestinal Motility Disorder	10	-	-	11	1	-
Constipation	7	-	-	8	-	-
Oral Discomfort	9	-	-	9	-	-
Skin and Subcutaneous						
Hand-and-Foot Syndrome**	53	17	-	6	1	-
Dermatitis	24	1	-	23	1	-
Skin Discoloration	7	-	-	5	-	-
Alopecia	6	-	-	21	-	-
General						
Fatigue/Weakness	32	3	-	38	3	-
Pyrexia	9	-	-	12	1	-
Neurological						
Paresthesia	9	-	-	5	-	-
Sensory Disturbance	6	-	-	11	-	-
Dizziness*	5	-	-	5	-	-
Metabolism						
Appetite decreased	20	1	-	25	2	-
Dehydration	4	2	-	6	2	-
Eye						
Eye Irritation	11	-	-	8	-	-
Respiratory						
Dyspnea	6	-	-	4	-	-
Cardiac						
Edema	5	-	-	3	-	-
Blood and Lymphatic						
Neutropenia	21	0.7	2	55	8	13
Thrombocytopenia	20	0.5	0.5	28	0.2	0.2
Anemia	80	2	0.2	82	1	0.3
Lymphopenia	93	29	8	92	30	8

Adverse Event	XELODA (n=596)			5-FU/LV (n=593)		
Body System/ Adverse Event	NCIC Grade					
	1 to 4	3	4	1 to 4	3	4
Hepatobiliary Hyperbilirubinemia	49	18	5	25	3	3

- Not observed or applicable.

* Excluding vertigo

** Based on the post-marketing experience, persistent or severe palmar-plantar erythrodysesthesia syndrome (grade 2 and above) can eventually lead to loss of fingerprints (see WARNINGS AND PRECAUTIONS).

In the pooled phase III metastatic colorectal studies, dose reductions occurred in 34% of patients treated with capecitabine and in 42% with 5-FU. Dose reductions also occurred later with capecitabine than 5-FU/LV (median time to dose reduction was 76 and 36 days, respectively).

The hospitalization rate for the treatment-related adverse events was 11.6% for capecitabine treated patients and 18.0% for 5-FU/LV-treated patients. The predominant treatment-related adverse events leading to hospitalization in capecitabine and 5-FU/LV-treated patients, respectively, were diarrhea (4.2% vs. 3.7%), dehydration (2.2% vs. 1.5%), and stomatitis (0.2% vs. 3.7%).

Metastatic Colorectal Cancer, Combination Therapy

XELODA in combination with oxaliplatin

The following table (Table 4) shows the most frequent ADRs ($\geq 5\%$) reported in patients with metastatic colorectal cancer who received second-line (Study NO16967) treatment with XELODA in combination with oxaliplatin (XELOX). The intensity of adverse events was graded according to the toxicity categories of the NCI CTCAE Grading System Version 3.0.

Table 4 Summary of ADRs in $\geq 5\%$ of Patients who Received Second-line Treatment with XELODA and Oxaliplatin for Metastatic Colorectal Cancer (Study NO16967)

Body system	XELOX ^a (N=311)		FOLFOX-4 ^b (N=308)	
	All	Grade 3/4	All	Grade 3/4
Adverse drug reaction	%	%	%	%
Gastrointestinal Disorders				
Nausea	60	4	56	3
Diarrhea	57	20	49	5
Vomiting	43	3	34	3
Stomatitis	14	<1	30	1
Abdominal pain	30	5	24	5
Constipation	16	2	26	3
Dyspepsia	11	<1	7	-
Abdominal pain upper	6	<1	6	<1

Body system	XELOX ^a (N=311)		FOLFOX-4 ^b (N=308)	
	All	Grade 3/4	All	Grade 3/4
Nervous system disorders				
Paraesthesia	33	4	32	3
Neuropathy peripheral	13	<1	10	-
Peripheral sensory neuropathy	13	<1	16	2
Dysgeusia	7	<1	11	-
Neuropathy	12	<1	9	<1
Dysaesthesia	10	<1	11	2
Dizziness	10	<1	9	-
Headache	10	<1	11	<1
Lethargy	6	2	6	<1
Hypoaesthesia	7	<1	6	<1
General disorders and administration site conditions				
Fatigue	41	7	42	9
Asthenia	19	3	18	5
Oedema Peripheral	5	<1	9	<1
Pyrexia	21	-	23	<1
Temperature intolerance	5	-	6	-
Chills	3	-	6	-
Blood and lymphatic system disorders				
Neutropenia	18	5	48	35
Thrombocytopenia	13	3	17	2
Anaemia	6	1	8	2
Metabolism and nutrition disorders				
Anorexia	32	4	27	2
Hypokalemia	8	4	5	3
Dehydration	6	3	5	2
Skin and subcutaneous tissue disorders				
Palmar-plantar erythrodysesthesia syndrome	23	4	6	<1
Rash	10	-	7	<1
Alopecia	1	-	6	-
Respiratory, thoracic and mediastinal disorders				
Cough	7	<1	15	-
Dysaesthesia pharynx	11	2	4	<1
Epistaxis	3	-	7	<1
Dyspnea	9	1	10	2
Pharyngolaryngeal pain	3	-	5	-
Musculoskeletal and connective tissue disorders				
Pain in extremity	6	<1	5	<1
Pain in jaw	5	<1	4	-
Pain in back	10	2	14	3
Myalgia	4	-	7	<1
Investigations				
Weight decreased	6	<1	6	<1

Body system	XELOX ^a (N=311)		FOLFOX-4 ^b (N=308)	
	All	Grade 3/4	All	Grade 3/4
Psychiatric disorders Insomnia	7	<1	12	-
Infections and Infestations Nasopharyngitis	4	-	6	<1
Vascular Disorders Flushing	3	-	6	-
Immune System Disorders Hypersensitivity	2	<1	6	4

^aXELOX: XELODA (1000 mg/m² twice daily for 2 weeks followed by a 7-day rest period) and oxaliplatin (130 mg/m² as a 2-hour infusion on day 1 every three weeks).

^bFOLFOX-4: leucovorin (200 mg/m² as a 2-hour infusion on days 1 and 2 every two weeks), 5-FU (400 mg/m² as a bolus injection, 600 mg/m² as a 22 hour infusion on days 1 and 2 every two weeks), and oxaliplatin (85 mg/m² as a 2 hour infusion on day 1 every two weeks).

8.5 Post-Market Adverse Reactions

The following additional adverse events have been identified during post-marketing use of XELODA. Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to XELODA exposure.

Table 8 Adverse Drug Reactions Reported in the Post Marketing Setting

System Organ Class (SOC)	ADR(s)
Gastrointestinal	Serious gastro-intestinal disorders have been reported in patients exposed to XELODA and include but are not limited to: necrotizing enterocolitis, ileus paralytic, gastrointestinal perforation and intestinal obstruction.
Cardiovascular	Thromboembolic events such as deep vein thrombosis, thrombophlebitis and pulmonary embolism have been reported.
Hepatobiliary disorders	Hepatic failure, Cholestatic hepatitis.
Renal and urinary disorders	Acute renal failure secondary to dehydration including fatal outcome (see WARNINGS AND PRECAUTIONS).
Immune	Angioedema, Cutaneous lupus erythematosus, severe skin reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) (see WARNINGS AND PRECAUTIONS)
Eye disorders	Lacrimal duct stenosis NOS, Corneal disorders including keratitis.
Nervous system disorders	Toxic leukoencephalopathy (see WARNINGS AND PRECAUTIONS).

Exposure to crushed or cut XELODA tablets

In the instance of exposure to crushed or cut XELODA tablets, the following ADRs

have been reported: eye irritation, eye swelling, skin rash, headache, paresthesia, diarrhea, nausea, gastric irritation, and vomiting.

9. DRUG INTERACTIONS

9.4 Drug-Drug Interactions

Sorivudine and analogues⁴: A clinically significant drug-drug interaction between sorivudine and 5-FU, resulting from the inhibition of dihydropyrimidine dehydrogenase by sorivudine, has been described. This interaction, which leads to increased fluoropyrimidine toxicity, is potentially fatal. Therefore, capecitabine must not be administered concomitantly with sorivudine or its chemically related analogues, such as brivudine. There must be at least a 4-week waiting period between end of treatment with sorivudine or its chemically related analogues such as brivudine and start of capecitabine therapy.

Phenytoin and Fosphenytoin: Increased phenytoin plasma concentrations have been reported during concomitant use of XELODA with phenytoin, suggesting a potential interaction. Formal drug-drug interactions studies with phenytoin have not been conducted, but the mechanism of interaction is presumed to be inhibition of the CYP 2C9 isoenzyme system by capecitabine (see subsection below, Cytochrome P450 2C9 Substrates). Patients taking phenytoin or fosphenytoin concomitantly with XELODA should be regularly monitored for increased phenytoin plasma concentrations and associated clinical symptoms.

Coumarin Anticoagulants: Altered coagulation parameters and/or bleeding have been reported in patients taking XELODA concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. These events occurred within several days and up to several months after initiating XELODA therapy and, in a few cases, within one month after stopping XELODA. In a drug interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC (+57%) of S-warfarin. These results suggest an interaction, probably due to an inhibition of the cytochrome P450 2C9 isoenzyme system by capecitabine. In a clinical interaction study, after a single 20 mg dose of warfarin, XELODA treatment increased the AUC of S-warfarin by 57% with a 91% increase in INR value. Patients taking coumarin-derivative anticoagulants concomitantly with XELODA should be monitored regularly for alterations in their coagulation parameters (PT or INR) and the anticoagulant dose adjusted accordingly.

Cytochrome P450 2C9 Substrates: No formal drug-drug interaction studies with capecitabine and other drugs known to be metabolized by the cytochrome P450 2C9 isoenzyme have been conducted. Care should be exercised when XELODA is co-administered with these drugs, which are metabolized by cytochrome P450 2C9 such as for example warfarin or phenytoin. Patients receiving concomitant XELODA and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored closely and the

⁴ sorivudine and its chemically related analogues, such as brivudine are not authorized for sale in Canada.

anticoagulant dose adjusted accordingly. Patients taking phenytoin concomitantly with XELODA should be regularly monitored for increased phenytoin plasma concentrations.

Antacid: The effect of an aluminum hydroxide and magnesium hydroxide-containing antacid (Maalox[®]) on the pharmacokinetics of capecitabine was investigated in 12 cancer patients. There was a small increase in plasma concentrations of capecitabine and one metabolite (5'-DFCR); there was no effect on the 3 major metabolites (5'-DFUR, 5-FU and FBAL).

Leucovorin: A phase I study evaluating the effect of leucovorin on the pharmacokinetics of capecitabine was conducted in 22 cancer patients. Leucovorin has no effect on the pharmacokinetics of capecitabine and its metabolites; however, the toxicity of capecitabine may be enhanced by leucovorin.

Oxaliplatin: No clinically significant differences in exposure to capecitabine or its metabolites, free platinum or total platinum occurred when capecitabine and oxaliplatin were administered in combination.

9.5 Drug-Food Interactions

The effect of food on the pharmacokinetics of capecitabine was investigated in 11 cancer patients. The rate and extent of absorption of capecitabine is decreased when administered with food. The effect on AUC_{0-∞} of the 3 main metabolites in plasma (5'-DFUR, 5-FU, FBAL) is minor. In all clinical trials, patients were instructed to take XELODA within 30 minutes after a meal. Therefore, since current safety and efficacy data are based upon administration with food, it is recommended XELODA be administered with food.

10. CLINICAL PHARMACOLOGY


10.1 Mechanism of Action

Capecitabine is a tumour- activated antineoplastic agent (antimetabolite) belonging to the novel fluoropyrimidine carbamate class. It was rationally designed as an orally administered precursor of 5'-deoxy-5-fluorouridine (5'-DFUR). Capecitabine is selectively activated to the cytotoxic moiety, 5-fluorouracil (5-FU), by thymidine phosphorylase in tumours.

Within normal and tumour cells, 5-FU is further metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) which cause cell injury by both DNA and RNA-derived mechanisms (see the DETAILED PHARMACOLOGY section for more information).

Bioactivation: Capecitabine is absorbed unchanged from the gastrointestinal tract, metabolized primarily in the liver by the 60kDa carboxylesterase to 5'-Deoxy-5-fluorocytidine (5'-DFCR) which is then converted to 5'-DFUR by cytidine deaminase, principally located in the liver and tumour tissue. Further metabolism of 5'-DFUR to the pharmacologically-active agent 5-FU

occurs mainly at the site of the tumour by thymidine phosphorylase (dThdPase), which has levels considerably higher in tumour tissues compared to normal tissues (see the following figure for the metabolic pathway of capecitabine). Healthy liver tissues also contain a relatively high activity of dThdPase. In human cancer xenograft models, capecitabine demonstrated a synergistic effect in combination with docetaxel which may be related to the upregulation of thymidine phosphorylase by docetaxel.



10.3 Pharmacokinetics

Pharmacokinetic Parameters: Table 12 below shows the pharmacokinetic parameters of capecitabine, 5'-DFCR, 5'-DFUR and 5-FU in plasma at steady-state (day 14) following administration of the recommended dose (1255 mg/m² b.i.d.) in 8 cancer patients. The peak of plasma concentrations of intact drug, 5'-DFCR, 5'-DFUR and 5-FU is reached rapidly and then concentrations decline with a short half-life for all species.

Table 12 Descriptive Statistics on the Pharmacokinetic Parameters Estimated on Day 14 after Administration of Capecitabine (1255 mg/m²) in 8 Cancer Patients

Parameter	Capecitabine	5'-DFCR	5'-DFUR	5-FU	FUH ₂	FBAL
C_{max} (µg/mL)	3.99 (56%)	1.71 (236%)	9.37 (94%)	0.709 (87%)	0.442 (103%)	5.32 (26%)
t_{max} (h)	1.50 (0.78-2.17)	2.00 (0.78-4.08)	2.00 (1.28-4.08)	2.00 (1.28-4.08)	2.28 (2.00-4.08)	3.34 (3.00-5.58)
AUC_{0-t} (µg.h/mL)	7.29 (32%)	3.97 (175%)	19.9 (57%)	1.62 (62%)	1.20 (153%)	30.0 (20%)
AUC_{0-∞} (µg.h/mL)	7.40 (34%)	5.21 (140%)	21.7 (63%)	1.63 (74%)	2.15 (67%)	35.2 (27%)
t_{1/2} (h)	0.85 (88%)	1.11 (80%)	0.66 (17%)	0.76 (25%)	1.14 (26%)	3.23 (40%)

Geometric means (CV) are reported for C_{max}, AUC_{0-t} and AUC_{0-∞}. Median values (min-max) are reported for t_{max}. Arithmetic means (CV) are reported for t_{1/2}.

After oral administration, plasma data indicate an extensive and rapid conversion to the first two metabolites in plasma, 5'-DFCR and 5'-DFUR. The peak plasma concentrations for the drug and its two first metabolites occurs shortly (median t_{max} of 1.50 to 2.0 h) after capecitabine administration. Concentrations then decline exponentially with half-lives of 0.85 h (arithmetic mean), 1.11 h and 0.66 h for intact drug, 5'-DFCR and 5'-DFUR, respectively. Following administration of 1255 mg/m², a high AUC_{0-∞} is obtained for 5'-DFUR (geometric mean = 21.7 µg•h/mL, CV = 63%, n = 8). On day 14, the systemic exposure (AUC) to 5-FU is approximately 13 times lower than the systemic exposure to 5'-DFUR.

In plasma, the peak of FBAL concentration occurred approximately 3 h after drug intake. The decline in FBAL concentration is characterized by a half-life of 3.23 ± 1.29 h. Plasma concentrations of FBAL are high (1.6 times those of 5'-DFUR and 22 times those of 5-FU), which probably reflects the extensive formation of 5-FU in the tumour and other tissues.

Absorption, Distribution, Metabolism and Excretion: Capecitabine reached peak blood levels in about 1.5 hours (T_{max}) with peak 5-FU blood levels occurring slightly later, at 2 hours. Administration with food decreases the rate of capecitabine absorption but only results in a minor decrease in the AUC's of 5'-DFUR and 5-FU (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION). Plasma protein binding of capecitabine and its metabolites is low (less than 60%) and is not concentration dependent. Capecitabine was primarily bound to human albumin (approximately 35%). Capecitabine is extensively metabolized to 5-FU. The enzyme dihydropyrimidine dehydrogenase hydrogenates 5-FU, the product of capecitabine metabolism, to the much less toxic, 5-fluoro-5, 6-dihydro-fluorouracil (FUH₂). Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fluoro-ureido-propionic acid (FUPA). Finally, β-ureido-propionase cleaves FUPA to α-fluoro-β-alanine (FBAL) which is

cleared in the urine. Over 70% of the administered capecitabine dose is recovered in urine as drug-related material, about 50% of it as FBAL.

Phase I studies evaluating the effect of XELODA on the pharmacokinetics of either docetaxel or paclitaxel and vice versa showed no effect by XELODA on the pharmacokinetics of docetaxel or paclitaxel (C_{max} and AUC) and no effect by docetaxel or paclitaxel on the pharmacokinetics of 5'-DFUR (the most important metabolite of capecitabine).

Pharmacokinetics in Colorectal Tumours and Adjacent Healthy Tissue: Following oral administration of capecitabine (1255 mg/m² b.i.d. 5 to 7 days) in patients with colorectal cancer, concentrations of 5-FU were significantly greater in primary tumour than in adjacent healthy tissue (geometric mean ratio 2.5; CI:1.5 to 4.1) and in plasma (geometric mean ratio 14).

Special Populations and Conditions

A population pharmacokinetic analysis was carried out after XELODA treatment of 505 patients with metastatic colorectal cancer dosed at 2500 mg/m²/day. Gender, race, presence or absence of liver metastasis at baseline, Karnofsky Performance Status, total bilirubin, serum albumin, ASAT and ALAT had no statistically-significant effect on the pharmacokinetics of 5'-DFUR, 5-FU and FBAL.

- **Geriatrics:** Based on the population pharmacokinetic analysis which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65, age has no influence on the pharmacokinetics of 5'-DFUR and 5-FU. The AUC of FBAL increased with age (20% increase in age results in a 15% increase in the AUC of FBAL). This increase is likely due to a change in renal function (see CLINICAL PHARMACOLOGY: *Renal Insufficiency*). However, the elderly may be pharmacodynamically more sensitive to the toxic effects of 5-FU (see WARNINGS AND PRECAUTIONS, Geriatrics and DOSAGE AND ADMINISTRATION).
- **Sex:** Based on population pharmacokinetic analysis including 202 females (40%) and 303 males (60%), gender has no influence on the pharmacokinetics of 5'-DFUR, 5-FU and FBAL.
- **Ethnic Origin:** Based on population pharmacokinetic analysis of 455 white patients (90.1%), 22 black patients (4.4%) and 28 patients of other race or ethnicity (5.5%), the pharmacokinetics of black patients were not different compared to white patients. For the other minority groups the numbers were too small to draw a conclusion.
- **Hepatic Insufficiency:** Capecitabine has been evaluated in patients with mild to moderate hepatic dysfunction due to liver metastases. Both C_{max} and AUC_{0-∞} of capecitabine, 5'-DFUR and 5-FU were increased by 49%, 33% and 28% and by 48%, 20% and 15%, respectively. Conversely, C_{max} and AUC of 5'-DFUR decreased by 29% and 35%, respectively. Therefore, bioactivation of capecitabine is not affected. There are no pharmacokinetic data on patients with severe hepatic impairment (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION).

- **Renal Insufficiency:** Based on a pharmacokinetic study in cancer patients with mild to severe renal impairment, there is no evidence for an effect of creatinine clearance on the pharmacokinetics of intact drug and 5-FU. Creatinine clearance was found to influence the systemic exposure to 5'-DFUR (35% increase in AUC when creatinine clearance decreases by 50%) and to FBAL (114% increase in AUC when creatinine clearance decreases by 50%). FBAL is a metabolite without antiproliferative activity; 5'-DFUR is the direct precursor of 5-FU.

As seen with 5-FU, the incidence of related grade 3 or 4 adverse events is higher in patients with moderate renal impairment (creatinine clearance 30-50 mL/min) (see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION).

For more detailed information on the pharmacokinetics of capecitabine, please refer to the DETAILED PHARMACOLOGY section.

11. STORAGE AND STABILITY

XELODA tablets should be stored at 15-30°C and in the original package.

12. SPECIAL HANDLING INSTRUCTIONS

Disposal of unused/expired medicines

The release of pharmaceuticals in the environment should be minimized. Medicines should not be disposed of via wastewater and disposal through household waste should be avoided. Use established “collection systems”, if available in your location.

Special handling using appropriate equipment and disposal procedures, should be taken as XELODA is a cytotoxic drug. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

PART II: SCIENTIFIC INFORMATION

13. PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: capecitabine

Chemical name: 5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine

Molecular formula and molecular weight: C₁₅H₂₂FN₃O₆; 359.35

Structural formula:



Physicochemical properties:

Physical Form: white to off-white crystalline powder
Solubility: Water 2.6 g/100 mL
pKa: 8.8 (in water and titrated with 0.1 N KOH with bubbling N₂)
Partition co-efficient: octanol/buffer: log P =4.4-0.98 (range for pH 5.0-9.5)
Melting Point: 120°C with decomposition

14. CLINICAL TRIALS

14.1 Trial Design and Study Demographics

In a phase I study with XELODA, the maximum-tolerated dose as a single agent in the treatment of patients with solid tumours was 3000 mg/m² when administered daily for 2 weeks, followed by a 1-week rest period. The dose-limiting toxicities were diarrhea and leucopenia.

14.2 Study Results

Colorectal Carcinoma: Adjuvant Colon Cancer

Data from one open-label, multicenter, randomized, controlled, non-inferiority, phase III clinical trial in patients with stage III (Dukes C) colon cancer supports the use of XELODA for the adjuvant treatment of patients with stage III colon cancer (X-ACT Study: M66001). In this trial, 1987 patients were randomized to treatment with monotherapy XELODA (1250 mg/m² twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles for 24 weeks) (N=1004) or 5-FU and leucovorin (Mayo regimen: 20 mg/m² leucovorin i.v. followed by 425 mg/m² i.v. bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks) (N=983). Although this trial used bolus 5-FU in the control arm, infusional 5-FU has been shown to be superior to bolus 5-FU.

The primary efficacy endpoint was disease-free survival. The original conditional approval was based on primary analysis at a median follow-up time of 3.8 years which showed XELODA was at least equivalent to i.v. 5-FU/LV in disease-free survival (p=0.0001, non-inferiority margin 1.2) with a trend towards superiority in disease-free survival. The full approval was based on an updated analysis at a median follow-up time of 6.9 years which confirmed XELODA to be at least equivalent to 5-FU/LV in disease-free survival although there was no longer a trend toward superiority in disease-free survival (p=0.06). A summary of the results is provided in Table 13. Compared with 5-FU/LV, XELODA was associated with lower incidence of stomatitis, neutropenia and febrile neutropenia but with a considerably higher incidence of hand-and-foot syndrome and hyperbilirubinemia in the adjuvant treatment of patients with Dukes Stage C colon cancer.

Figure 1: Kaplan-Meier Estimates of Disease-free Survival (All Randomized Population)




Table 13 Efficacy of XELODA vs 5-FU/LV in Adjuvant Treatment of stage III (Dukes Stage C) Colon Cancer

Design	Drug/Dosage	No. of Patients Enrolled -Demographic Data	Results of Primary Analysis – median follow-up 3.8 years	Results of Updated Analysis –median follow-up 6.9 years
PIVOTAL PHASE III STUDY (X-ACT Study) randomized, controlled, multicenter patients with stage III (Dukes' stage C) colon cancer	capecitabine 2500 mg/m ² /day for 2 weeks with a 1 week rest period [given as 3 week cycles for a total of 8 cycles (24 weeks)]	N=1004 Age (yrs) - Md: 62; range: 25 - 80 M/F: 542(54%)/ 461(46%) ECOG Score: 0 (%) 849 (85) 1 (%) 152 (15) Node Status ^a : N1 (%) 695 (69) N2 (%) 305 (30) Other (%) 4 (0.4)	All Randomized Population: Disease-Free Survival Hazard Ratio ^b = 0.87 (95% C.I. 0.75-1.00); p ^c = 0.053 3-year disease-free survival rate capecitabine - 64% 5-FU/LV - 61%	All Randomized Population: Disease-Free Survival Hazard Ratio ^b = 0.88 (95% C.I. 0.77-1.01); p ^c = 0.068 5-year disease-free survival rate capecitabine – 60.8% 5-FU/LV – 56.7%
	5-FU/leucovorin (LV) Mayo regimen - 20 mg/m ² leucovorin I.V. followed by 425 mg/m ² I.V. bolus 5-FU on days 1 to 5, every 28 days [given as 4 week cycles for a total of 6 cycles (24 weeks)]	N=983 Age (yrs) - Md: 63; range: 22 - 82 M/F: 532(54%)/ 451 (46%) ECOG Score: 0 (%) 830 (85) 1 (%) 147 (15) Node Status ^a : N1 (%) 694 (71) N2 (%) 288 (29) Other (%) 1 (0.1)	Overall Survival Hazard Ratio ^b = 0.84 (95% C.I. 0.69-1.01; p ^c = 0.071) 3-year overall survival rate capecitabine - 81% 5-FU/LV - 78% Per Protocol Population: Disease-Free Survival Hazard Ratio ^b = 0.89 (95% C.I. 0.76-1.04); p ^c = 0.157 3-year disease free survival rate capecitabine - 65% 5-FU/LV - 63% Overall Survival Hazard Ratio ^b = 0.90 (95% C.I. 0.73-1.10); p ^c = 0.298 3-year overall survival rate capecitabine – 83% 5-FU/LV – 80%	Overall Survival Hazard Ratio ^b = 0.86 (95% C.I. 0.69-1.01; p ^c = 0.060) 5-year overall survival rate capecitabine – 71.4% 5-FU/LV – 68.4% Per Protocol Population: Disease-Free Survival Hazard Ratio ^b = 0.92 (95% C.I. 0.80-1.06); p ^c = 0.2743 5-year disease free-survival rate capecitabine – 60.9% 5-FU/LV – 58.4% Overall Survival Hazard Ratio ^b = 0.93 (95% C.I. 0.73-1.09); p ^c = 0.357 5-year overall survival rate capecitabine – 72% 5-FU/LV – 70.5%

^aN1- tumor in 1-3 regional lymph nodes; N2- tumor in ≥ 4 regional lymph nodes

^b Capecitabine versus 5-FU/LV; Non-inferiority margin of 1.20 corresponds to the retention by XELODA of approx. 75% of the 5-FU/LV effect on DFS

^c Wald chi square test for differences of XELODA vs 5-FU/LV

Metastatic Colorectal Cancer

Data from two multicenter, randomized, controlled phase III clinical trials involving 603 patients and one randomized phase II trial of 34 patients support the use of XELODA in the first-line treatment of patients with metastatic colorectal carcinoma (refer to Table 14).

Table 14 Clinical Studies in Metastatic Colorectal Carcinoma - Monotherapy

-Design -Diagnosis	Drug/Dosage	No. of Patients Enrolled -Demographic Data	Results
<p>PIVOTAL PHASE III STUDIES</p> <p><u>Study 1:</u></p> <p>randomized, controlled, multicenter</p>	<p>-capecitabine 2500 mg/m²/day for 2 weeks with a 1 week rest period (given as 3 week cycles)</p> <p>-5-FU/leucovorin (LV) Mayo regimen*</p>	<p>N=302</p> <p>Age (yrs) - Md: 64; range: 23 -86</p> <p>M/F: 181(60%)/ 121(40%)</p> <p>Karnofsky PS- Md: 90%; range: 70 - 100</p> <p>Colon /Rectum: 222 (74%)/ 79 (26%)</p> <p>Prior radiation therapy: 52 (17%)</p> <p>Prior adjuvant 5-FU: 84 (28%)</p> <p>N=303</p> <p>Age (yrs) - Md: 63; range: 24 - 87</p> <p>M/F: 197(65%)/ 106(35%)</p> <p>Karnofsky PS- Md: 90%; range: 70 - 100</p> <p>Colon /Rectum: 232 (77%)/ 70 (23%)</p> <p>Prior radiation therapy: 62 (21%)</p> <p>Prior adjuvant 5-FU: 110 (36%)</p>	<p>-overall response rate: capecitabine - 21% 5-FU/LV - 11% (p=0.0014)</p> <p>-median time to progression: capecitabine - 128 days 5-FU/LV - 131 days (p=0.90)</p> <p>-median survival: capecitabine - 380 days 5-FU/LV - 407days (p=0.24)</p>

-Design -Diagnosis	Drug/Dosage	No. of Patients Enrolled -Demographic Data	Results
<u>Study 2:</u> randomized, controlled, multicenter	-capecitabine 2500 mg/m ² /day for 2 weeks with a 1 week rest period (given as 3 week cycles) -5-FU/leucovorin (LV) Mayo regimen*	N=301 Age (yrs) - Md: 64; range: 29 - 84 M/F: 172(57%)/ 129(43%) Karnofsky PS- Md: 90%; range: 70 - 100 Colon /Rectum: 199 (66%)/ 101 (34%) Prior radiation therapy: 42 (14%) Prior adjuvant 5-FU: 56 (19%) N=301 Age (yrs) - Md: 64; range: 36 - 86 M/F: 173(57%)/ 128(43%) Karnofsky PS- Md: 90%; range: 70 - 100 Colon /Rectum: 196 (65%)/ 105 (35%) Prior radiation therapy: 42 (14%) Prior adjuvant 5-FU: 41 (14%)	-overall response rate: capecitabine - 21% 5-FU/LV - 14% (p=0.027) -median time to progression: capecitabine - 137 days 5-FU/LV - 131 days (p=0.68) -median survival: capecitabine - 404 days 5-FU/LV - 379 days (p=0.30)
PHASE II STUDY randomized, open label	-capecitabine 1331 mg/m ² /day (continuous) -capecitabine 2510 mg/m ² /day (intermittent) -capecitabine 1657 mg/m ² /day/ leucovorin 60 mg/day (intermittent)	39 34 35 Patients with advanced and/or metastatic colorectal carcinoma	-objective response rate: 22% 25% 24%

*20 mg/m² leucovorin I.V. followed by 425 mg/m² I.V. bolus 5-FU on days 1 to 5, every 28 days.

XELODA was superior to 5-FU/LV for objective response rate in Study 1 and Study 2. The response rate observed in patients receiving the Mayo regimen was consistent with the published literature. It was also observed that in patients who received prior adjuvant chemotherapy the objective response rate was 15.3% and 14.5% for capecitabine and 5.5% and 4.4% (Study 1 and 2, respectively) for 5-FU/LV. There was no difference in time to disease progression and survival as compared to 5-FU/LV for both studies.

Combination therapy – Second-line treatment of metastatic colorectal cancer

Data from a multicenter, randomized, controlled phase III clinical study (NO16967) support the use of XELODA in combination with oxaliplatin for the second-line treatment of metastatic colorectal cancer. In this trial, 627 patients with metastatic colorectal carcinoma who have received prior treatment with irinotecan in combination with a fluoropyrimidine regimen as first-line therapy were randomized to treatment with XELOX or FOLFOX-4. For the dosing schedule of XELOX and FOLFOX-4, refer to Table 15 below.

Table 15 Treatment Regimens in Study NO16967

	Treatment	Starting Dose	Schedule
FOLFOX-4	Oxaliplatin	85 mg/m ² IV 2 h	Oxaliplatin on Day 1, every 2 weeks
	Leucovorin	200 mg/m ² IV 2 h	Leucovorin on Day 1 and 2, every 2 weeks
	5-Fluorouracil	400 mg/m ² IV bolus, 600 mg/ m ² IV 22 h	5-fluorouracil IV bolus/infusion, each on Days 1 and 2 , every 2 weeks
XELOX	Oxaliplatin	130 mg/m ² IV 2 h	Oxaliplatin on Day 1, every 3 weeks
	Capecitabine	1000 mg/m ² oral bid	Capecitabine oral bid for 2 weeks (followed by 1 week off treatment)

5-Fluorouracil: IV bolus injection immediately after leucovorin

XELOX is at least equivalent to FOLFOX-4 in terms of progression-free survival in the per protocol population and intent-to-treat population in the investigator assessments. Progression-free survival by the IRC assessment also met the NI margin of 1.23 (HR = 0.93; 95% CI [0.74; 1.17]). Exploratory subgroup analyses for PFS (EP population) and OS (ITT population) for age suggest that XELOX may be less effective than FOLFOX-4 in patients ≥ 65 years of age (HR 1.32, 95% CI, 0.98-1.78 and HR 1.34, 95% CI, 1.00-1.80, respectively).

No quality of life data was collected. The median follow up at the time of the primary analyses in the intent-to-treat population was 2.1 years; data from analyses following an additional 6 months of follow up are also included in the table below.

Table 16 Key Non-Inferiority Efficacy Results for the Primary Analysis and 6-month Follow-up Data (PPP and ITT Populations, Study NO16967)

PRIMARY ANALYSIS					
PFS by Investigator Assessment*					
	XELOX		FOLFOX-4		
Population	# events	Median Time to Event (Days)	# events	Median Time to Event (Days)	HR (97.5% CI)
PPP	244	154	247	168	1.03 (0.87; 1.24)
ITT	301	144	301	146	0.97 (0.83; 1.14)
OS					
ADDITIONAL 6-MONTHS OF FOLLOW UP					
ITT	270	363	270	382	1.02 (0.86; 1.21)

*PFS by IRC assessment (PPP) met the NI margin of 1.23 (HR = 0.93; 95% CI [0.74; 1.17])

Breast Carcinoma:

XELODA has been evaluated in breast cancer clinical trials in combination with docetaxel and as monotherapy. Table 17 summarizes data from a pivotal combination trial as well as from one pivotal and two supportive monotherapy phase II clinical trials.

XELODA in Combination with Docetaxel: The dose of XELODA used in combination with docetaxel in the phase III clinical trial was based on the results of a phase I study, where a range of doses of docetaxel given every 3 weeks in combination with an intermittent regimen of XELODA were evaluated. The combination dose regimen was selected based on the tolerability profile of the 75 mg/m² every 3 weeks of docetaxel in combination with 1250 mg/m² twice daily for 14 days of XELODA administered every 3 weeks. The approved dose of 100 mg/m² of docetaxel administered every 3 weeks was the control arm of the phase III study.

As shown in Table 17, XELODA in combination with docetaxel resulted in statistically significant improvement in time to disease progression, overall survival and objective response rate compared to monotherapy with docetaxel.

Health Related Quality of Life (HRQoL) was assessed using EORTC QLQ-C30 (version 2) and Breast Cancer Module of the EORTC (BR23). HRQoL was similar in the two treatment groups. Approximately 11% of patients in the combination arm and 10% in the monotherapy arm did not complete a quality of life questionnaire at least once either at baseline or during the treatment phase.

Table 17 Clinical Studies in Breast Carcinoma

-Design -Diagnosis	Drug/Dosage	No. Women Enrolled	Results
222			
PIVOTAL STUDY - MONOTHERAPY			
<p>-open label</p> <p>-females with advanced or metastatic breast cancer refractory to previous paclitaxel therapy: (77% resistant, 23% failed paclitaxel; 41% resistant, 26% failed anthracycline therapy; 82% prior 5-FU exposure).</p>	<p>-capecitabine 2510 mg/m²/day for 2 weeks with a 1 week rest period (given as 3 week cycles)</p>	<p>162 (135 measurable disease)</p>	<p>-overall response rate (ORR) intent-to-treat (n=135): 20% (95% CI:13.6-27.8); 3 complete responses</p> <p>-ORR (standard population, n=117): 23% (min. 6 weeks therapy)</p> <p>-median duration of response: 241 days</p> <p>-median time to progression: 93 days</p> <p>-median survival: 384 days</p> <p>-clinical benefit response: positive 29 pts. (20%); stable 45 pts. (31%). In 51 pts. with baseline pain ≥20 mm (visual analogue scale), 24 pts. (47%) positive response in pain intensity (≥50% decrease)</p>
SUPPORTIVE STUDIES - MONOTHERAPY			
<p>-open label, randomized, parallel group</p> <p>-females ≥55 with advanced or metastatic breast cancer without previous chemotherapy (other than adjuvant treatment)</p>	<p>-capecitabine 2510 mg/m²/day for 2 weeks with a 1 week rest period (given as 3 week cycles)</p> <p>-Cytoxan, methotrexate, 5FU (CMF) 600/40/600 mg/m² iv q3 weeks.</p>	<p>95</p>	<p>-capecitabine response rate: 25% (95%CI: 14%-37%)</p> <p>-CMF response rate: 16% (95% CI: 5%-33%)</p> <p>-median time to disease progression: capecitabine-132 days; CMF-94 days</p>
<p>-open-label, randomized parallel group</p> <p>-females with disease progression within 12 months of previous anthracycline treatment</p>	<p>-capecitabine 1331 mg/m²/day (continuous) for 6 weeks</p> <p>-capecitabine 2510 mg/m²/day for 2 weeks with a 1 week rest period (given as 3 week cycles) (intermittent)</p> <p>-paclitaxel 175 mg/m²/q 3weeks</p>	<p>44</p>	<p>-capecitabine response rate (intermittent arm): 36% (95% CI: 17-59%); 3 complete responses</p> <p>-paclitaxel response rate: 21% (95% CI: 6-46%).</p> <p>-median time to disease progression: capecitabine 92 days; paclitaxel 95 days.</p>

synthesis, thereby inhibiting cell proliferation. The second mechanism results from the incorporation of FUTP into RNA in place of UTP, thereby preventing the correct nuclear processing of ribosomal RNA and messenger RNA. These effects are most marked on rapidly proliferating cells, such as tumour cells, which utilize 5-FU at a higher rate.

Clinical Pharmacokinetics:

The pharmacokinetics of capecitabine and its metabolites have been evaluated in 11 studies in a total of 213 cancer patients at a dosage range of 502 to 3514 mg/m²/day. The parameters of capecitabine, 5'-DFCR and 5'-DFUR measured on days 1 and 14 were similar. AUC of 5-FU was 30% higher on day 14, but did not increase subsequently (day 22). At therapeutic doses, the pharmacokinetics of capecitabine and its metabolites were dose proportional, except for 5-FU. The elimination half-life of both capecitabine and 5-FU were about 45 minutes.

Absorption: The gastrointestinal absorption of capecitabine and its metabolites (5'-DFCR, 5'-DFUR and 5-FU) was rapid (median 2 hours; range 0.5 to 5 hours). Capecitabine is extensively absorbed since at least 70% of the dose was recovered in urine with low variability (CV of 30%).

Distribution: Binding of ¹⁴C-capecitabine, ¹⁴C-5'-DFCR and ³H-5'-DFUR to human plasma proteins were determined *in vitro* by ultrafiltration. The concentration ranges used (0.2/0.5 to 200/500 µg/mL) encompassed the concentrations observed in plasma species *in vivo*. Plasma protein binding of capecitabine is low (54%, 10% and 60% for capecitabine, 5'-DFCR and 5'-DFUR, respectively) and is not concentration-dependent. Capecitabine was primarily bound to human albumin (approximately 35%).

Excretion: In three studies, concentrations of capecitabine and its metabolites (5'-DFCR, 5'-DFUR, 5-FU, FUH2, FUPA and FBAL) were measured in urine. Over 70% of the capecitabine dose was recovered in urine as drug-related material. The majority of the dose was recovered as FBAL (approximately 50%).

15. NON-CLINICAL TOXICOLOGY

The tables presented on the following pages provide the findings of the main toxicology, mutagenicity/genotoxicity and reproduction/teratology studies performed with capecitabine:

Acute Toxicity:

Title	Species/ Strain	No./Sex/ Dose	Dose (mg/kg)	Duration of Observations/ Route of Administration	Maximum Non- Lethal Dose	Target Organs/Systems of Toxicity
Mouse Acute Study	Mouse / BDF1	5	250, 375, 500	14 days Intravenous	> 250 - < 375 mg/kg for males > 375 - < 500 mg/kg for females	<u>High-Dose:</u> 3 males and 2 females died. Transient ↓ spontaneous motor activity immediately after to 1 hour after dosing. <u>Mid-Dose:</u> One male died. Transient ↓ spontaneous motor activity immediately after to 1 hour after dosing. <u>Low-Dose:</u> No adverse effects observed.
Mouse Acute Study	Mouse / BDF1	5	1000, 2000	14 days Oral (gavage)	> 2000 mg/kg (limit dose)	<u>Low & High Doses:</u> Transient ↓ spontaneous motor activity from 15 minutes after dosing to 1 hour at 1000 mg/kg and 2-4 hours at 2000 mg/kg (↓ respiratory rate & prostration at high dose only). Transient ↓ food consumption, males, on day of dosing.
Rat Acute Study	Rat / (SD-Slc)	5	1000, 2000	14 days Oral (gavage)	> 2000 mg/kg (limit dose)	<u>Low Dose:</u> ↓ spontaneous motor activity and muscle relaxation (1 female) from 15-30 minutes after dosing. <u>High Dose:</u> ↓ spontaneous motor activity, muscle relaxation, and immobility in males and females, and slight salivation in 1 female from 15 minutes-4 hours after dosing
Monkey Pyramiding Study	Monkeys / Cynomolgus	2 males only	500, 1000, 2000 ¹	14 days after final dosing Oral (naso-gastric)	> 2000 mg/kg (limit dose)	<u>Low Dose:</u> Emesis within 15 minutes of dosing; loose feces/diarrhea in 1 monkey the day after dosing. <u>Mid-Dose:</u> Emesis 1.5 or 6 hours post-dosing; loose feces/diarrhea in 1 monkey 6 hours after dosing. <u>High Dose:</u> Emesis within 15 minutes of dosing; salivation immediately after dosing; loose feces/diarrhea for approximately 1 week after dosing.

¹ 500 mg/kg (day 1), 1000 mg/kg (day 4), 2000 mg/kg (day 7)

Subchronic and Chronic (Long-Term) Toxicology Studies:

Title	Species/Strain	No./Sex/Dose	Dose (mg/kg/day)	Duration / Route of Administration	Target Organs / Systems of Toxicity
4-Week Mouse Study	Mouse / BDF1	6	0 198 395 791	4 weeks Oral (gavage)	<u>Mid & High Doses:</u> Slight anemia, ↑BUN (slight); ↑spleen weight (slight); enlarged nuclei and degenerated crypt cells in small intestine, ↑extramedullary hematopoiesis in spleen <u>High Dose:</u> ↓BMC (slight); ↓thymus weight (slight); slight atrophic changes in thymus and spleen, degeneration of hematopoietic cells in bone marrow
13-Week Mouse Study	Mouse / BDF1	151 ¹	0 198 395 791/593 ²	13 Weeks + 4 weeks Recovery Oral (gavage)	<u>Mid & High Dose:</u> ↓RBC, ↑MCV, MCH, PLT; ↑spleen weight, ↓ovary weight; splenic extramedullary hematopoiesis, increased ratio of neutrophil myelocytes & degenerated erythroblasts in bone marrow, changes in female reproductive organs, regressive change of gastrointestinal tract <u>High Dose:</u> Mortality (11/30); ↓body weight, food intake; emaciation, ↓spontaneous motor activity, loose feces; ↓HCT, Hb, BMC; ↓testis & epididymis weights; atrophy of lymph node nodules and of thymus, ↓erythroblasts in bone marrow, changes in male reproductive organs. Found dead & moribund sacrificed mice also showed hyposthenia, hypothermia, bradypnea, or convulsion; ↓WBC, ↑reticulocytes; ↓thymus & uterus weights, ↑relative adrenal weight; atrophy of epidermis/sebaceous glands/hair follicles in skin. <u>Recovery High Dose:</u> ↑PLT, reticulocyte, BMC; enlarged spleen with increased weight; extramedullary hematopoiesis in spleen, ↑neutrophil myelocytes in bone marrow
4-Week Rat Study	Rat / (SD-Slc)	5	0 179.5 359 538.5	4 Weeks Oral (gavage)	<u>High Dose:</u> Slight ↓body weight gain and food intake (males); slight degeneration of rectal crypt cells
26-Week Rat Study	Rat / (SD-Slc)	20	0 179.5 359 538.5	26 Weeks Oral (gavage)	<u>High and Mid Doses:</u> ↓Body weight gain and food intake (males); ↑MCH, MCV (very slight), ↓serum total protein (very slight/males); proteinuria <u>High Dose:</u> (males only) ↓RBC (very slight); ↓urine volume and ↑specific gravity (slight); slight histopathologic changes in rectum (degenerated crypt cells, dilatation of glandular lumina, enlarged nuclei of crypt cells or epithelium)

¹ 10 for 13 week dosing, 5 for recovery.

² The high dose was changed from 791 mg/kg/day to 593 mg/kg/day on day 37.

Title	Species/ Strain	No./ Sex/ Dose	Dose (mg/kg/ day)	Duration / Route of Adminis- tration	Target Organs / Systems of Toxicity
4-Week Monkey Study & Toxico- kinetics	Monkey/ Cynomolgus (<i>Macaca fascicularis</i>)	3 (High dose: males only)	0 35.9 179.5 359	4 Weeks Oral (gavage)	<p><u>Mid Dose:</u> Decrease in duodenal and ileal mucosal folds</p> <p><u>Mid & High Doses:</u> Loose feces, diarrhea; ↓body weight & food intake; ↓WBC, BMC; ↓thymus weight; gastrointestinal changes (dilated glandular lumina, enlarged nuclei of epithelial cells and crypt cells, atrophic glands), atrophic acinar cells in pancreas, atrophic lymph follicles in lymph nodes, spleen and tonsils, atrophic thymus, hypoplasia of hematopoietic cells in bone marrow, atrophy of acinar cells in salivary glands</p> <p><u>High Dose:</u> Mortality - 2 males sacrificed moribund; emesis; in addition, 2 males sacrificed moribund showed ↓spontaneous motor activity, emaciation, hypothermia, lying on the side, staggering gait; atrophic mucosa and glands, enlarged glandular lumina, enlarged nuclei of mucosal epithelial cells and crypt cells in stomach and small intestine, atrophy of mucosal epithelium of tongue and esophagus, degeneration and hypertrophy of cortical cells, and hemorrhage in cortex of adrenals</p>
13-week Monkey Study & Toxico- kinetics	Monkey / Cynomolgus (<i>Macaca fascicularis</i>)	4	0 54 108 215/162 ¹	13 Weeks + 4 Weeks Recovery Oral (gavage)	<p><u>Mid & High Doses:</u> Loose feces; ↓RBC, WBC, HCT, Hb; small thymus and spleen, atrophied splenic nodules, decrease of lymphocyte in thymic cortex.</p> <p><u>High Dose:</u> Mortality - 1 male died, 1 female sacrificed moribund; ↓food intake; ↓thymus & spleen weights; atrophied lymph nodules in tonsil.</p> <p>In addition, monkeys that died or were sacrificed moribund showed poor appetite, diarrhea, staggering gait, emesis, lying on the belly, ↓spontaneous motor activity, emaciation, hypothermia, pale oral mucosa; ↓body weight; ↓BMC, ↑platelet; enlarged adrenal & ↑weight; ↓adipose tissue, atrophy of thymus, regressive degeneration of gastrointestinal tract, lymphatic, & hematopoietic organs.</p> <p>No findings after recovery period.</p>

¹ Days 0-31:215 mg/kg/day; days 32-34: cessation of administration; days 35-90: 162 mg/kg/day

Title	Species/ Strain	No./ Sex/ Dose	Dose (mg/kg/ day)	Duration / Route of Administration	Target Organs / Systems of Toxicity
26-Week Monkey Study	Monkey / Cynomolgus <i>(Macaca fascicularis)</i>	3	0 18 54 144	26 Weeks Oral (gavage)	<p><u>High Dose:</u> Mortality (1 female sacrificed moribund); loose feces; ↓WBC (segmented neutrophils, lymphocytes), RBC, HCT and Hb; atrophy of thymus & lymphoid follicle of spleen.</p> <p>In addition, female monkey sacrificed moribund showed diarrhea, ↓spontaneous motor activity, loss of appetite, pale oral mucosa, emaciation, prone position, hypothermia, bradypnea; ↓body weight & food intake; ↓BMC, ↑relative lymphocytes, ↓total cholesterol, glucose, Ca, Na, K, Cl, ↑creatinine, BUN, α-1 globulin; enlarged adrenals, small thymus, liquid feces in large intestine, no contents in stomach or small intestine; ↓absolute weights of heart, liver, kidney, thymus, ↑relative weights of brain, lung, adrenals; histopathologic changes in digestive system (degeneration or hyperplasia of mucosal epithelium, hyperplasia of muscularis mucosa, fibroplasia of submucosa, blunting and fusing of villi); atrophy of lymphoid follicles of spleen; atrophic thymus; lymphocyte depletion of mesenteric lymph node; decreased cellularity of bone marrow; hypoplasia of squamous epithelium in skin, mammary gland, tongue, esophagus, vagina; atrophy of hair follicle of skin; degranulation of acinar cell in pancreas (islet cells of the pancreas were unaffected).</p>
52-Week Monkey Study & Toxico- kinetics	Monkey / Cynomolgus <i>(Macaca fascicularis)</i>	4	0 36 72 108	52 weeks Oral (gavage)	<p><u>All treated groups:</u> Dose-related increase of post-dosing salivation, slight ↓WBC, dosage-related ↑myeloid left shift.</p> <p><u>High Dose:</u> Regurgitation, ↓relative thymus weight (marginal) with ↓lymphocytes in thymic cortex and proliferated hematopoietic cells in bone marrow.</p>

Carcinogenicity Study:

Title	Species/Strain	No./Sex/Dose	Dose (mg/kg/day)	Duration / Route of Administration	Target Organs / Systems of Toxicity
24-Month Mouse Carcinogenicity Study	Mouse / BDF1	50/sex/group	0 - Control -1 0 - Control - 2 30, 60, 90	24-Month Oral (dietary admixture)	<p><u>Low Dose:</u> ↑ MCV, MCH (females only)</p> <p><u>Mid Dose:</u> ↑ MCV, MCH, ↓ RBC, ↓ testes weights</p> <p><u>High Dose:</u> ↓RBC, Hb, HCT, ↑ MCV, MCH, platelets</p> <p>↓ Thymus and testes weight (males only)</p> <p>There was no evidence of an oncogenic potential</p>

Mutagenicity and Genotoxicity Studies:

Title	Assay System	Concentration of Capecitabine Assayed	Duration of Exposure	Genotoxic and Other Findings
Bacterial Cell Gene Mutation (Exploratory)	Ames Test: standard plate incorporation method using strains TA98 & TA100 of <i>Salmonella typhimurium</i> with & without metabolic activation (S9 mix)	4 to 1000 µg/plate	48 hrs	No mutagenic activity observed with or without metabolic activation.
Gene mutation test in Cultured Mammalian Cells	Chinese hamster lung cells V79/HPRT with and without metabolic activation	100 to 4000 µg/mL (without metabolic activation) 100 to 5000 µg/mL (with metabolic activation)	16 hrs (without metabolic activation) 5 hrs (with metabolic activation)	No mutagenic activity observed with or without metabolic activation. <u>Cytotoxicity</u> Relative cell viability: 42-51% at 4000 µg/mL without metabolic activation 50-92% at 5000 µg/mL with metabolic activation
Chromosome Aberration (<i>in vitro</i>)	Human peripheral blood lymphocytes with and without metabolic activation	50 to 500 µg/mL (without metabolic activation) 250 to 3600 µg/mL (with metabolic activation)	24 & 48 hrs (without metabolic activation) 3 hrs (with metabolic activation)	<u>Without metabolic activation:</u> Clastogenic and cytotoxic at doses of 250 & 500 µg/mL. <u>With metabolic activation:</u> Not clastogenic or cytotoxic.
Chromosome Aberration (<i>in vivo</i>)	Mouse micronucleus test Strain: Füllinsdorf Moro Albino	<u>Oral Dose (mg/kg)</u> 500 1000 2000	<u>Post-dose</u> 24 hrs 24 hrs 24 & 48 hrs	The frequency of micronucleated polychromatic erythrocytes was not statistically significantly increased at any of the sampling times. No signs of toxicity in bone marrow cells.

Reproduction and Teratology Studies:

Title	Species/ Strain	No./Sex/ Dose	Dose (mg/kg/ day)	Duration /Route of Administration	Target Organs / Systems of Toxicity
Mouse Fertility Study	Mouse / BDF1	24	0 190 380 760	<p><u>Males:</u> 28 days before, through confirmation of fertility</p> <p><u>Females:</u> 14 days before, through mating & until day 6 of gestation</p> <p style="text-align: center;">Oral (gavage)</p> <p>Recovery: following cessation of treatment, high-dose females that had unsuccessfully mated were re-mated with control or high-dose males.</p>	<p>Parental mice: No drug-related deaths.</p> <p><u>High Dose:</u> ↓body weight gain & food intake, emaciation, slight ↓spontaneous motor activity; ↓mating index (due to disturbed estrous cycle) & female fertility index; ↓testes & epididymes weights, degeneration & decrease of spermatocytes & spermatids in testes, ↑degenerative spermatogenic cells in epididymes in males; no live fetuses, ↑resorptions (early deaths).</p> <p><u>Mid Dose:</u> ↓live fetuses, ↑resorptions (early deaths).</p> <p>Fetus: Slight ↓female fetal body weights, slight ↑fetuses with external anomalies.</p> <p>Recovery: Adverse effects reversed. No adverse effects on reproductive performance, fetal viability, or body weight; no fetal malformations.</p>
Mouse Embryo-toxicity & Teratogenicity Study	Mouse / BDF1	ca. 20 mated females	0 190 395 791	<p style="text-align: center;">Day 6 - 15 of gestation (1st day of gestation = day 0)</p> <p style="text-align: center;">Oral (gavage)</p>	<p>Dams: No drug-related deaths.</p> <p><u>All treated groups:</u> Dose-dependent ↓body weight gain & food intake; dose-dependent ↓live fetuses and ↑early resorption rate.</p> <p><u>High Dose:</u> No live fetuses.</p> <p><u>High & Mid Doses:</u> Most had complete resorptions.</p> <p><u>Mid Dose:</u> Only one dam with live fetuses.</p> <p><u>Low Dose:</u> Slight ↑late resorptions.</p> <p>Fetus: <u>Mid Dose:</u> Oligodactyly. <u>Mid and Low Dose:</u> ↓fetal body weight. <u>Low Dose:</u> Cleft palate, anophthalmia, microphthalmia, oligodactyly, polydactyly, syndactyly, kinky tail; dilated cerebral ventricles.</p>
Title	Species/	No./Sex/	Dose	Duration /Route of	Target Organs / Systems of Toxicity

	Strain	Dose	(mg/kg/ day)	Administration	
Mouse Embryo-toxicity & Teratogenicity Study (Supplement to Study Ref. 2302)	Mouse/ BDF1	ca. 20 mated females	0 25 50 100	Day 6 - 15 of gestation (1st day of gestation = day 0) Oral (gavage)	Dams: All groups: No drug-related deaths. <u>High Dose:</u> Slight ↓body weight gain and food intake. Fetus: No treatment-related effects.
Mouse Embryo-toxicity & Teratogenicity Study (Supplementary Segment II - F1 pup evaluation)	Mouse/ BDF1	ca. 20 mated females	0 50 100 200	Day 6 - 15 of gestation (1st day of gestation = day 0) Oral (gavage)	Dams: No drug-related deaths. <u>High Dose:</u> Slight ↓body weight gain and food intake; slightly prolonged gestation period. Pups: <u>High Dose:</u> ↓Live neonates, ↓viability index from day 0 to day 4 after birth, slight ↓body weight gain, ↑number of pups with skeletal abnormalities (domed head, kinky tail), retardation of ossification, slight ↑ambulation in open field test. <u>High & Mid Doses:</u> Deaths with domed head and hydrocephaly; swollen spleen at necropsy with extramedullary hematopoiesis.
Monkey Preliminary Embryo-toxicity & Terato-genicity Study	Monkey / Cynomolgus (<i>Macaca fascicularis</i>)	2 pregnant females	90 180	Day 20 - 50 of gestation Oral (gavage)	Dams: No deaths in any group. <u>High Dose:</u> Abortion (1 between days 40 - 50 of gestation). <u>High and Low Doses:</u> Embryonic death (1 in each group, high dose on day 40 of gestation, low dose on day 50 of gestation); ↓food intake in dams with embryonic death and abortion. Fetus: High and Low Doses: No placental or external anomalies in dead embryos or live fetuses. <u>Low Dose:</u> One normal male fetus; no abnormalities in body weight, or visceral or skeletal findings.

Title	Species/ Strain	No./Sex/ Dose	Dose (mg/kg/ day)	Duration /Route of Administration	Target Organs / Systems of Toxicity
Monkey Embryo- toxicity & Terato- genicity Study	Monkey / Cynomolgus (<i>Macaca fascicularis</i>)	5 pregnant females	0 22.5 45 90	Day 20 - 50 of gestation Oral (gavage)	<p>Dams No maternal deaths or adverse effects. <u>High Dose:</u> Abortion (1 between days 30 - 40 of gestation). <u>Low Dose:</u> Embryonic death (1 on day 30 of gestation).</p> <p>Fetus: No treatment-related changes observed in the examinations of live fetuses.</p>
Mouse Peri- and Post-natal Study (Segment III)	Mouse/ BDF1	ca. 20 mated females (F0 generation)	0 100 200 400	From day 15 of gestation, through lactation to day 20 post-partum (First day of gestation = gestation day 0) (First day of lactation = lactation day 0) Oral (gavage)	<p>Dams: No treatment-related deaths or adverse effects.</p> <p>Pups (F1): No treatment-related findings.</p>

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PrXELODA[®]
capecitabine tablets

Read this carefully before you start taking **PrXELODA**[®] and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **PrXELODA**[®].

Serious Warnings and Precautions

Serious side effects include:

- **Severe dehydration** may cause rapid loss of kidney functions including kidney failure. This may lead to death.
- Sudden death due to **heart problems** including irregular heartbeat.
- **Severe skin reactions** such as hand-and foot syndrome, Stevens-Johnson Syndrome [SJS] and Toxic Epidermal Necrolysis [TEN].
- **Severe toxicity including death in patients who do not have an enzyme called dihydropyrimidine dehydrogenase (DPD)**. If you lack this enzyme you should not take XELODA. Your healthcare professional might check to see if you have this enzyme before you can take XELODA.
- **Increased bleeding** in patients also taking medicines that thin the blood. This can happen as soon as a few days after you start taking XELODA. It can also happen later during treatment and possibly even within 1 month after you stop taking XELODA. Before you start taking XELODA, tell your healthcare professional if you are also taking a blood thinner medicine, like warfarin. Your doctor might check the clotting time of your blood before you take XELODA and while you are taking it. Increased bleeding in patients also taking medicines that thin the blood. This can happen as soon as a few days after you start taking XELODA. It can also happen later during treatment and possibly even within 1 month after you stop taking XELODA. Before you start taking XELODA, tell your healthcare professional if you are also taking a blood thinner medicine, like warfarin. Your doctor might check the clotting time of your blood before you take XELODA and while you are taking it.

See “Serious side effects and what to do about them” table for more information. See “Serious side effects and what to do about them” table for more information.

What is XELODA used for?

XELODA is used to treat patients with:

- Stage III colon cancer (Duke's stage C) which is a condition where the cancer of the colon has spread to other areas. It is used after surgery has been performed.
- Cancer of the colon or rectum that is called metastatic. Metastatic means the cancer has spread to other parts of the body.
- Metastatic cancer of the colon or rectum in combination with another cancer medicine called oxaliplatin. In these patients, it is used after another medicine called irinotecan was tried previously.
- Breast cancer that is advanced or metastatic after therapy with other medicines has not worked.
- Breast cancer that is advanced or metastatic in combination with another cancer medicine called docetaxel. In these patients it is used when other medicines have not worked.

How does XELODA work?

XELODA belongs to a family of medicines called fluoropyrimidines. These medicines interfere with the growth of cells that divide rapidly in the body like cancer cells. XELODA is converted to the medicine fluorouracil in the body. It prevents the growth of cancer cells and kills them.

What are the ingredients in XELODA?

Medicinal ingredients: capecitabine

Non-medicinal ingredients: croscarmellose sodium, hydroxypropyl methylcellulose, iron oxides (yellow and red), lactose anhydrous, magnesium stearate microcrystalline cellulose, talc, titanium dioxide.

XELODA comes in the following dosage forms:

As tablets containing 150 mg and 500 mg capecitabine.

Do not use XELODA if you:

- Are allergic to capecitabine,5-fluorouracil.
- Are allergic to any of the other non-medicinal ingredients in XELODA.
- Have severe kidney problems.
- Have been told that you do not have an enzyme called dihydropyrimidine dehydrogenase (DPD).
- Are being treated now or have been treated in the last 4 weeks with brivudine, sorivudine or similar classes of medicines¹ as treatment for herpes zoster (chickenpox or shingles).

¹sorivudine and brivudine are not approved in Canada.

It is not known if XELODA is safe and effective in patients younger than 18 years of age

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take XELODA. Talk about any health conditions or problems you may have, including if you:

- Are allergic to other medications, food and dyes.
- Are taking phenytoin (Dilantin®) or fosphenytoin (Cerebyx®). Your doctor may need to check the levels of phenytoin in your blood more often.
- Are taking docetaxel.
- Have heart problems.
- Have liver problems.
- Have kidney problems.
- Are pregnant, plan to become pregnant or are breastfeeding or are planning to breastfeed.
- Are 60 years of age or older.

Other warnings you should know about:

- XELODA may impair fertility in females and males.
- **Female Patients:** You should not become pregnant while you are taking XELODA. This is because it can harm your unborn child. Before you start taking XELODA, it is recommended that you test to make sure you are not pregnant. You must use effective birth control while you are taking XELODA and for nine months after you stop taking it. Talk to your healthcare professional about effective methods of birth control.
- **Male Patients:** You should not father a child if you are taking XELODA. If your female partner is of childbearing age you must use effective birth control while you are taking XELODA and for 3 months after you stop taking it. Talk to your healthcare professional about effective methods of birth control for you and your partner.
- You should stop breastfeeding during treatment with XELODA and for 2 weeks after the final dose.
- If you are over 65 years old, you may be more sensitive to the toxic side effects of XELODA. Watch more carefully for possible diarrhea, nausea, and vomiting.
- If you experience persistent or severe hand-and-foot syndrome while taking XELODA, it can eventually lead to loss of fingerprints. This could impact your identification by fingerprint scan.
- **Driving and using machines:** XELODA may make you feel dizzy, nauseous or tired. This may affect your ability to drive a car or operate machines. Before driving or using machines, wait until you are feeling well again.
- **Your doctor may tell you to decrease the dose or stop XELODA treatment for a while if side effects appear.** If caught early, most of these side effects usually improve after you stop taking XELODA. If they do not improve within 2 to 3 days, call your doctor again. After side effects have improved, your doctor will tell you whether to start taking XELODA again and what is the right dose for you.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with XELODA:

- Medicine used to treat seizures such as phenytoin and posphenytoin.
- Blood thinner medicine such as warfarin and phenprocoumon.
- Medicine used to treat heartburn and acid indigestion such as Maalox®.
- Leucovorin, a medicine used to prevent the harmful effects of cancer chemotherapy medication.
- Certain medicines used specifically for treating viral infections such as sorivudine and brivudine.²

²sorivudine and brivudine are not approved in Canada.

How to take XELODA:

- Take XELODA exactly as your healthcare professional tells you to.
- Swallow tablets whole with water.
- Take XELODA within 30 minutes after finishing a meal.
- Do not crush or cut XELODA tablets.
- If you cannot swallow XELODA tablets, speak to your healthcare professional.
- Stay under your healthcare professional's care while taking XELODA.
- Your healthcare professional might change your dose or stop your treatment if you develop certain side effects.

Usual dose:

The usual dose of XELODA depends on your body surface size. Your healthcare professional will tell you how much XELODA to take.

You may need to take a combination of 150 mg and 500 mg tablets. **To get the right dose it is very important that you identify the tablets correctly each time you take XELODA.** Taking the wrong tablets could result in an overdose (too much medication) or underdose (too little medication).

Take the tablets twice a day (morning and evening doses) as your doctor prescribed. Do not take more than your prescribed dose, more often or for a longer time than your doctor told you to.

XELODA is taken in 21 day cycles. This means you take XELODA for 14 days and then stop taking it for 7 days. It is important to have this rest period. Your doctor will tell you how many cycles of treatment you will need.

For the treatment of colon cancer following complete surgical removal, XELODA is usually taken for eight 21-day cycles (i.e. for a total of 24 weeks or approximately 6 months).

Overdose:

If you think you, or a person you are caring for, have taken too much XELODA, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you forget a dose of XELODA do not take the missed dose at all. Take your next dose at the usual time and check with your doctor. Do not take a double dose.

What are possible side effects from using XELODA?

These are not all the possible side effects you may have when taking XELODA. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- Constipation
- Skin irritation
- Fever
- Pins and needles sensation
- Loss of appetite
- Eye irritation
- Indigestion
- Heartburn
- Hair loss
- Taste altered
- Dizziness
- Nail changes, deformation, or abnormality
- Pain in limb
- Headache
- Trouble sleeping
- Muscle pain

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
VERY COMMON			
Diarrhea		✓	
Tiredness or fatigue		✓	
Nausea		✓	
Vomiting		✓	
Reduced white blood cell, red blood cells and platelets in the		✓	

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
blood: bleeding, bruising, chills, fatigue, fever, infections, weakness.			
Stomatitis (inflammation of the mouth, tongue and throat): sores, ulcers, redness, pain or swelling of the mouth including inside, the tongue or the throat, problems eating.		✓	
Hand-foot Syndrome: tingling, numbness, pain, swelling, redness or blisters of the palms of the hands or soles of feet.		✓	
COMMON			
Infection: cough, fever, pain during urination, sore throat		✓	
Increased chance of unusual bleeding		✓	
Dehydration: increased thirst, dry or sticky mouth, headache, less urination, dark yellow urine.		✓	
Heart problems: chest pain, abnormal heart rate, fainting, heart skipping a beat, shortness of breath, swelling of ankles or legs, weakness.		✓	
UNCOMMON			
Liver problems: abdominal pain, dark urine, fatigue, light-coloured stool, loss of appetite, nausea, vomiting, yellowing of the skin or eyes (jaundice).		✓	
Kidney problems: back and abdominal pain, change in the colour of urine, drowsiness, confusion or coma, fatigue, swelling of the legs and feet, nausea, vomiting, water retention, and weight gain.		✓	
VERY RARE			
Leukoencephalopathy (brain disease): lack of coordination or balance, loss of vision, personality or mood changes, trouble speaking, weakness.		✓	
UNKNOWN			

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Angioedema (swelling in your body that is serious): swelling of face, lips, tongue, throat, eyes and/or mouth, hives, rash, voices changes, a harsh vibrating noise when breathing, severe difficulty breathing, fainting sensation or collapse.		✓	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Talk to your healthcare professional if you experience **any diarrhea, vomiting or nausea. Stop taking XELODA and call your doctor immediately if you notice any of the following additional symptoms in regards to your diarrhea, vomiting or nausea.** Your doctor can then adjust XELODA to a dose that is right for you. This should help to reduce the side effects and stop them from getting worse.

Diarrhea:

- an additional 4 bowel movements a day beyond what is normal or any diarrhea at night
- if you have a colostomy, an increase in loose, watery fluid in your colostomy bag
- any diarrhea together with soreness of the mouth affecting your ability to drink enough fluids

Vomiting:

- vomiting more than once in 24 hours, especially if you also have diarrhea

Nausea:

- loss of appetite or eating less food than usual each day

Side effects may differ when taking XELODA in combination with docetaxel compared with taking XELODA alone. In addition to the above side effects listed, increased tears, joint pain, muscle pain, and sore throat be occur. Talk to your doctor for more information on the possible side effects that may occur when taking XELODA in combination with docetaxel.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Keep out of reach and sight of children.

Store at room temperature (15-30°C), in the original package.

Special handling using appropriate equipment and disposal procedures, should be taken as XELODA can be harmful to normal cells of the body. Any unused medicinal product or waste material should be disposed in accordance with local requirements.

If you want more information about XELODA:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website www.rochecanada.com, or by calling 1-800-762-4388.

This leaflet was prepared by Hoffmann-La Roche Limited.

©Copyright 1998 – 2021 Hoffmann-La Roche Limited. XELODA® is a registered trade-mark of F. Hoffmann-La Roche AG, used under license.

All other trade-marks are the property of their respective owners.

Last Revised APR-19-2021